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Vitamin E is a group of compounds that are considered to be the most important 
lipophilic antioxidants, however there is still much unknown about the biological actions of the 
various forms of vitamin E as well as the mechanisms that influence the concentration of vitamin 
E forms in tissues.  Despite the common predominance of mainly γ-tocopherol (γ-TOH) in the 
diet, α-TOH is present in serum and tissues at levels 5-6 times that of γ-TOH. The biological 
rational for this selectivity remains an enigma.  The focus of this work was on the selective post-
absorptive catabolism of non-α-TOH forms via the vitamin E-ω-oxidation pathway.  Cytochrome 
P450 4F2 (CYP4F2) is the only known human enzyme shown to display TOH-ω-hydroxylase 
activity.  In an effort to investigate the role of TOH-ω-hydroxylase activity in vitamin E 
metabolism and status, the functional murine ortholog of CYP4F2 was identified and the 
consequences of its deletion on vitamin E metabolism and status were determined.  In vivo and in 
vitro studies revealed Cyp4f14 to be the major, but not the only, vitamin E-ω-hydroxylase in 
mice, and to have critical function in regulating body-wide vitamin E status. Disruption of 
Cyp4f14 expression resulted in hyper-accumulation of γ-TOH in mice fed a soybean oil diet in 
which the major tocopherol was γ-TOH. Supplementation of Cyp4f14-/- mice with high levels of 
δ- and γ-TOH exacerbated the tissue enrichment of these forms of vitamin E.  Through the use of 
 metabolic cage studies, previously unappreciated mechanisms of vitamin E elimination were 
discovered, which served to counterbalance the metabolic deficit observed in Cyp4f14
-/-
 mice.  
Fecal elimination of unmetabolized TOHs was determined to be a high capacity mechanism to be 
minimize diet induced accumulation of TOHs, especially at high dietary levels.  Additionally, 
novel ω-1 and ω-2 vitamin E hydroxylase activities were discovered and were found to 
quantitatively important vitamin E elimination mechanisms.  Cyp4f14
-/- 
mice also revealed the 
existence of other hepatic TOH-ω-hydroxylase enzyme(s).  Therefore genetically modified mice, 
in which no CYP activity was present in the liver, were utilized in order to eliminate all hepatic 
vitamin E metabolism.  Metabolic cage studies revealed the presence of vitamin E hydroxylase 
activity in non-hepatic tissues.  Mouse and human small intestine mucosa were found to have 
TOH-ω-hydoxylase activity, representing at least one site of extra-hepatic vitamin E metabolism.  
Lastly, the use of cell culture studies demonstrated that two polymorphisms in CYP4F2 
functionally alter TOH-ω-hydroxylase activity, which may play a role in vitamin E status in 
humans.  Overall, the current works lends new insights into the physiological role of the TOH-ω-
oxidation pathway as well as reveals novel mechanisms of vitamin E metabolism in both mice 
and humans, which play an important role in the regulation of vitamin E status.  
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INTRODUCTION 
 
 
Vitamin E is a family of chemically-related lipophilic compounds, comprised of 
tocopherols (TOHs) and tocotrienols (T3s), which differ in the number and position of the 
methyl groups around the chromanol ring and in the saturation and stereochemistry of the phytyl 
tail (Fig. I.1). First discovered in 1922 to be required for fertility in rats (1), these compounds are 
considered to be the most important liphophilic radical-quenching antioxidants in cell 
membranes and lipid stores.  While all forms of vitamin E possess roughly similar radical 
scavenging activity in vitro (2, 3), α-TOH has been the focus of research due to the fact that it is 
the form that is found in the highest concentration in plasma and tissues of animals. 
 
 
 
 
 
 
 
 
Fig. I.1. The chemical Structure of vitamin E. α-, γ-, and δ-TOH have 3, 2 and 
1 methyl groups on the polar head of the compound, respectively.  The 
corresponding T3s have three double bonds in the side chain of the compound. 
 
Vitamin E is synthesized in plants and is consumed in humans largely through vegetable 
oils; the content and ratio of vitamin E forms varies by oil.  The typical North American diet 
contains 2-4 times as much γ-TOH compared to α-TOH (4, 5) due to the prevalence of corn and 
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soybean oils.  Despite the consumption of mainly γ-TOH, α-TOH is present in serum and tissues 
at levels 5-6 times that of γ-TOH (6).  The preferential accumulation of α-TOH (“the α-TOH 
phenotype”) is widespread in the animal kingdom and yet the biological advantage of this 
phenotype is currently unknown.  The α-TOH phenotype is thought to be brought about by two 
mechanisms: the α-tocopherol transfer protein (α-TTP) and the vitamin E-ω-oxidation pathway, 
although the relative contribution of these mechanisms to the α-TOH phenotype has not been 
investigated. 
All forms of vitamin E are absorbed apparently to the same extent and transported in the 
plasma via lipoproteins.  Vitamin E is taken up by the liver with lipoproteins and is thought to be 
resecreted into the plasma via very low density lipoproteins (VLDL).  α-TTP, a cytosolic liver 
protein, is thought to facilitate the resecretion of TOHs from the liver into the plasma for 
transport to peripheral tissues (7, 8).  The relative affinities of α-TTP to the various forms of 
vitamin E is thought to play a major role in controlling vitamin E levels in the plasma and 
tissues.  α-TTP has the highest affinity for RRR-α-TOH in vitro, and much lower affinity for 
other TOHs and T3s (9), thereby presumably contributing to the preferential retention of α-TOH 
in animal tissues (10, 11).  While it is still unclear the extent to which α-TTP can bind to and 
facility the secretion of non-α-TOH forms in the body, studies in which α-TTP has been 
disrupted in mice certainly demonstrates the importance of α-TTP in maintaining plasma and 
tissue α-TOH levels.  α-TTP knockout mice display severe vitamin E deficiency and 
neurological symptoms that can be overcome by large dietary doses of α-TOH (reviewed in 
(12)).  Indeed, humans with genetic defects in α-TTP display severe vitamin E deficiency as well 
as neurological abnormalities, termed ataxia with vitamin E deficiency (AVED) (13).  
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The second mechanism that is involved in the α-TOH phenotype is the preferential post-
absorptive catabolism of non-α-TOH forms of vitamin E via the vitamin E-ω-oxidation pathway 
(Fig. I.2).  The first and rate limiting step of the vitamin E-ω-oxidation pathway of vitamin E 
metabolism is the ω-hydroxylation of one of the two terminal (13') methyl groups on the phytyl 
side chain of TOHs and T3s.  ω-Hydroxylation is followed by oxidation to the carboxy form and 
a series of side chain shortening steps, ultimately leading to short-chain, water soluble 
metabolites that can be excreted in the urine (14).   Although the most commonly studied 
metabolites are the shortest-chain metabolites (3'- and 5'-COOH), this pathway can produce 
seven metabolites, including the original 13'-OH product, the 13'-COOH product, and five 
subsequent n-2 COOH products. 
 
 
 
 
 
 
 
 
 
 
Figure I.2 The TOH-ω-oxidation pathway of γ-TOH. The first and rate-
limiting step of the TOH-ω-oxidation pathway of vitamin E metabolism is the ω-
hydroxylation of one of the terminal methyl groups of the compound, followed by 
oxidation to the carboxy form, and a series of side-chain shortening steps, leading 
to water-soluble metabolites that can be excreted in the urine. 
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The human cytochrome P450 4F2 (CYP4F2) expressed predominantly in liver has been 
identified as a human vitamin E-ω-hydroxylase (14).  The cytochrome P450 (CYP) superfamily 
of enzymes catalyze a vast number of catalytic reactions, including the metabolism of lipids, 
steroids, and xenobiotics.  These endoplasmic reticulum-bound enzymes require NADPH and the 
co-enzyme cytochrome P450 reductase (CPR) for the source and transfer of electrons to the CYP 
enzyme.  While enzymatic redundancy is common within in the P450 family, CYP4F2 is the 
only known enzyme to have vitamin E-ω-hydroxylase activity (14).  Importantly, CYP4F2 
displays substrate preference, such that non-α-TOH forms of vitamin E are metabolized to a 
greater extent than α-TOH, thereby potentially contributing to the α-TOH phenotype.  
Specifically, T3s are metabolized to the greatest extent by CYP4F2, followed by δ-TOH, γ-TOH, 
and lastly α-TOH which is metabolized less efficiently than all other forms of vitamin E (15). 
This dissertation was aimed at determining the role of TOH-ω-hydroxylase activity in 
vitamin E metabolism and status through the use of two knockout mouse models: 1) disruption 
of Cyp4f14, a mouse ortholog of CYP4F2 and 2) a liver-specific disruption of the Cpr gene, (L-
Cpr) eliminating all CYP activity in the liver.  Additionally, we characterized the functional 
effect of two common non-synonymous single nucleotide polymorphisms (SNPs) in the human 
CYP4F2 gene on TOH-ω-hydroxylase activity.  Collectively, this work clarifies the importance 
of the TOH-ω-oxidation pathway as well as illuminates novel pathways and mechanisms in 
preventing accumulation of non-α-TOH forms of vitamin E.  
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CHAPTER 1 
DISRUPTION OF MOUSE CYTOCHROME P450 4f14 (Cyp4f14) CAUSES SEVERE 
PERTURBATIONS IN VITAMIN E METABOLISM 
Introduction 
Vitamin E is a family of hydrophobic 6-hydroxy chromanols synthesized by plants whose 
function is thought to be the scavenging of lipophilic free radicals in cell membranes or lipid 
stores. Of nine known family members, several, particularly the tocopherols with saturated side 
chains, are common in the diet. However, while all possess roughly similar radical scavenging 
activity in vitro (2, 3), one, α-tocopherol (α-TOH), preferentially accumulates in animal tissue. 
While the typical North American diet contains 2-4 times as much γ-TOH as compared to α-
TOH due to the prevalence of soybean and corn oils (4, 5), α-TOH is present in serum at levels 
5-6 times that of γ-TOH (6). This preferential accumulation of α-TOH (the “α-TOH phenotype”) 
is widespread throughout the animal kingdom; however the biological advantage of this 
conservation remains an enigma. The preferential accumulation of α-TOH is apparently 
facilitated by two activities: preferential retention of α-TOH by the hepatic tocopherol transfer 
protein (α-TTP) (9, 16), and extensive post-absorptive catabolism of vitamers other than α-TOH 
by vitamin E-ω-hydroxylase (15). The relative contribution of these two activities in vivo has not 
been investigated. Vitamin E-ω-hydroxylase activity has been observed in Drosophila, with 
similar substrate specificity to that of the human activity, suggestive of a biological importance 
and evolutionary advantage of this highly conserved activity (17). 
We previously identified cytochrome P450 4F2 (CYP4F2) as a human vitamin E-ω-
hydroxylase (18). CYP4F2 catalyzes the ω-hydroxylation of one of the terminal methyl groups 
of the 16-carbon branched side chain of tocopherols and tocotrienols (T3s, with three double 
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bonds in the side chain). This oxidation is the first and rate-limiting step in the ω-oxidation 
pathway of vitamin E catabolism, and represents the only reported enzyme-mediated pathway of 
vitamin E metabolism. Following the initial ω-hydroxylation event, tocopherols and tocotrienols 
undergo a series of side chain shortening steps, analogous to fatty acid β-oxidation, yielding 
short chain carboxychromanol metabolites that are excreted in urine (19-21). In the human, 
CYP4F2 is expressed predominantly in the liver (22), and was initially identified as a ω-
hydroxylase of leukotriene B4 (LTB4). While several human CYP enzymes other than CYP4F2 
have been shown to ω-hydroxylate LTB4, including CYP4F3A (leukocyte) and CYP4F3B 
(liver)(23), CYP4F2 remains the only human enzyme demonstrated to metabolize vitamin E.  
We hypothesized that TOH-ω-hydroxylase activity is essential for establishing and 
maintaining the α-TOH phenotype. To test this hypothesis, we sought to identify the ortholog of 
CYP4F2 in mice, disrupt its expression by homologous recombination, and determine the 
consequences of its ablation on tocopherol metabolism and status. 
Experimental Procedures 
Materials - Trizol reagent, Superscript First Strand Synthesis Kit, pcDNA3.1/Hygro+ and 
Platinum PCR Supermix High Fidelity were purchased from Invitrogen (Carlsbad, CA), and 
primers from Integrated DNA Technologies (Coralville, Iowa). QIA Shredder Spin Columns, 
RNeasy Mini Kit, and RNase-free DNase were purchased from Qiagen (Valencia, CA). High 
Capacity cDNA Reverse Transcription Kit, Taqman Universal Master Mix and all Taqman 
assays were obtained from Applied Biosystems (Foster City, CA). Rabbit anti-human CYP4F2 
antibody and pre-immune (control) IgG were purchased from Research Diagnostics (Concord, 
MA). Tocopherols were obtained from Matreya, LLC (Pleasant Gap, PA). γ-T3 was a gift from 
Volker Berl (BASF Global, Schwarzheide, Germany). The internal standards d9-α-TOH and d9-
7 
 
α-CEHC were custom synthesized by J. Swanson (Cornell University, Ithaca, NY). Pyridine and 
N, O-Bis-[trimethylsilyl]trifluoracetamide containing 1% trimethylchlorosilane were purchased 
from Pierce Chemical (Rockford, IL). COS-7 cells were obtained from American Type Culture 
Collection (Manassas, VA). Sesamin was acquired from Cayman Chemical (Ann Arbor, MI), 
and bovine serum albumin, NADPH, β-glucuronidase (from Escherichia coli), and sulfatase 
(from Aerobacter aerogenes) were purchased from Sigma-Aldrich (St. Louis, MO). Wild type 
C57B/6J mice were obtained from Jackson Laboratory (Bar Harbor, ME). Rodent chow (Teklad 
7912) was purchased from Teklad Diets (Madison, WI) and modified AIN-93G rodent diet was 
manufactured by DYETS Inc (Bethlehem, PA).  
Immunoinhibition of mouse liver microsomal TOH-ω-hydroxylase by anti-human 
CYP4F antibody - Microsomes were prepared from fresh mouse liver by standard differential 
centrifugation. Liver was minced and homogenized using a Teflon/glass homogenizer in five 
volumes ice cold 15 mM HEPES buffer containing 0.25 M sucrose, 1 mM EDTA, and 1 mM 
phenylmethanesulfonylfluoride [PMSF], pH 7.4), then centrifuged at 10,000 x g for 20 min at 
4˚C. The supernatant was centrifuged at 100,000 x g for 1 h at 4˚C. The microsomal pellet was 
resuspended in 0.1 mM sodium phosphate (NaP) buffer containing 1 mM EDTA, 0.1 mM 
Dithiothreitol (DTT) and 20% glycerol. Microsomal protein concentration was determined by a 
Bradford-based Bio-Rad assay using bovine serum albumin (BSA) as the standard. Microsomes 
were pre-incubated with 1, 8, or 25 μg of anti-human CYP4F2 IgG antibody or 25 μg pre-
immune (control) IgG for 30 min on ice. TOH-ω-hydroxylase activity was determined as 
previously described (18), using  60 μM δ-TOH-BSA complex as substrate. 
BLAST comparison of human CYP4F2 with muring Cyp sequences - A comparison of 
the protein sequence of human CYP4F2 (NCB Accession #AAC27730.1) with that of all 
8 
 
reported murine proteins was conducted using the BLASTP program 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and the RefSeq protein database. A BLAST comparison 
of the amino acid sequence of the putative substrate binding domain of CYP4F2 (residues 69-
115, (24)), was also conducted. Two Cyp enzymes reported to be expressed in murine liver, 
Cyp4f14 and Cyp4f15 (25), were selected for further investigation based on high levels of 
homology with human CYP4F2. 
Cloning, expression, and assessment of TOH-ω-hydroxylase activity of Cyp4f14 and 
Cyp4f15 - Total RNA was extracted from mouse liver using Trizol reagent and reverse 
transcribed using Superscript First Strand Synthesis Kit. Cyp4f14 and Cyp4f15 cDNA was 
amplified from mouse liver RNA by one-step RT-PCR using primers based on the published 
sequences of murine liver Cyp4f14 cDNA (26) (GenBank Accession Number AB037541) and 
Cyp4f15 (GenBank Accession Number BC021377). The cDNA was restricted and ligated into 
pCDNA3.1/Hygro+ vector using the HndIII and Xho I restriction enzymes, and correct 
sequences confirmed by sequencing. The Cyp4f14 and Cyp4f15 genes (in the 
pCDNA3.1/Hygro+) were transfected into COS-7 cells. Forty-eight hours post-transfection, cells 
were exposed to hygromycin (200 μg/ml). Discrete colonies were picked after about 3 weeks in 
the selection media. Expression of Cyp4f14 and Cyp4f15 protein was verified by Western 
blotting using anti-CYP4F2 antibody which cross-reacts with other CYP4F (human) and Cyp4f 
(mouse) enzymes due to the high sequence homology, according to the manufacturer.  
Total cell membrane fractions from homogenates of COS-7 cultures were prepared by 
ultracentrifugation (100,000 x g). TOH-ω-hydroxylase activity was assessed in aliquots of COS-
7 cell membranes using δ-TOH as substrate as previously described (18). Preparations were 
compared at similar Cyp4f14/4f15 protein expression levels as determined by Western blot. 
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TOH-ω-hydroxylase activity and sesamin sensitivity of murine Cyp4f14 in COS-7 cells 
- A COS-7 clone expressing Cyp4f14 was incubated with a mixture of 20 μM each α-TOH, γ-
TOH, and δ-TOH, with or without 1 μM sesamin, for 48 h. Media was extracted and assayed for 
the presence of ω-oxidation metabolites of the three substrate tocopherols by gas 
chromatography-mass spectrometry (GC-MS) as previously described (27). 
Generation of Cyp4f14-null mice - The gene targeting vector was designed to target 
exons 2-5, which includes the putative substrate binding domain of Cyp4f14 (24), with the 
insertion of an IRES/LacZ/Neo/PolyA cassette to allow the tracing of gene expression (Fig. 1.1).  
Murine 129/SvEv embryonic stem cells were transfected, and integration of the genomic 
construct at the predicted site within the Cyp4f14 locus was confirmed by long-distance PCR 
using probes external to the targeted region (3' homologous arm and 5' homologous arm). 
Following ES cell expansion and karyotyping, selected clones were microinjected into C57BL/6 
blastocysts and implanted into psuedopregnant female mice. Male germline chimeras carrying a 
Cyp4f14 mutant allele were backcrossed with wild-type C57BL/6J females. Heterozygous F1 
progeny were intercrossed to obtain F2 mice that were homozygous wild-type (Cyp4f14
+/+
), 
heterozygous null (Cyp4f141
+/-
) and homozygous null (Cyp4f14
-/-
) for the targeted allele. Use of 
mice was in accordance with protocols approved by the Cornell Institutional Animal Care and 
Use Committee and following the National Institutes of Health guidelines for laboratory animal 
use.  
Genotyping of Cyp4f14 deficient mice - Genomic DNA was prepared from 0.2 cm tail 
snips using the HotSHOT method (28). Genomic DNA (50-200 ng) was used directly for PCR 
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Figure 1.1. Strategy of disruption of Cyp4f14 in the mouse. Genomic structure 
of Cyp4f14 locus (top), the Cyp4f14 gene targeting construct containing a IRES/ 
LacZ/Neo/PolyA cassette (middle), and the disrupted locus in which exons 2-5 
have been replaced (bottom). The arrows marked A, B, and C show the location 
of primers used for confirmation of germline transmission and tail snip 
genotyping. The arrows marked C, D, E, and F indicate the location of primers 
used for long distance PCR analysis, confirming the integration of the targeting 
construct into the Cyp4f14 locus. 
 
amplification with Platinum PCR SuperMix High Fidelity. Wild-type primers 
CTGGACATGTTTGAGCACG (forward; primer A) and GAACCACAGGCTAAGTCCATC 
(reverse; primer B) and a primer specific for the neomycin insert 
TCTGGATTCATCGACTGTGG (forward; primer C) were used for PCR amplification. The 
cycling protocol was as follows: 94˚C, 2 min (1 cycle); 94˚C, 15 s; 60˚C, 30 s; 68˚C, 1 min (35 
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cycles) and 68˚C, 7 min (1 cycle). The PCR products were separated on a 2% agarose gel 
yielding a 365 bp band for wild-type mice and 480 bp band for Cyp4f14-null mice (Fig. 1.3A). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3A. PCR genotyping of Cypf14 animals. Tail DNA was extracted from 
F2 littermates of a heterozygous cross and subjected to PCR using primers 
specific for the wild-type (365 bp) and mutated (480 bp) alleles. 
 
Experimental diets - Initial studies were conducted in mice fed Teklad 7912, a 
commercial chow-type diet containing low concentrations of δ- and γ-TOH. Subsequent studies 
utilized a modified AIN-93G semipurified diet designed to be rich in γ-TOH in the form of 
soybean oil, the most prevalent vegetable oil in North America. Samples of diets were ground 
using a mortar and pestle and lipids were extracted using hexane-methyl tert-butyl ether (MTBE) 
(2:1). Lipid extracts were dried and derivatized using pyridine and N,O-
Bis(trimethylsilyl)trifluoroacetamide (BSTFA)/1% tri-methy silyl (TMS), and tocopherols 
quantified by GC-MS using d9-α-TOH as internal standard. Tocopherol content of the chow and 
soybean oil diets, hereafter referred to as γT-10 and γT-165 denoting their respective 
concentration of γ-TOH is presented in Table 1.1.  
Feeding studies - Mice of all three genotypes weaned onto the γT-10 diet at 21 days of 
age were fed the diet for three weeks. Cyp4f14
+/+ 
and Cyp4f14
-/- mice weaned onto the γT-165 
diet were fed the diet for six weeks. At the end of the feeding periods, mice were deeply  
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anesthetized by isoflurane inhalation and exsanguinated via cardiac puncture. Heparinized blood 
was centrifuged at 6,000 x g for 5 min, and serum frozen at -80˚C until analysis. Liver tissue 
samples were flash frozen in liquid nitrogen for RT-PCR and vitamin E analysis. The remainder 
of the liver was immediately used for microsomal preparation as described above. Samples of 
additional tissues (kidney, lung, heart, testis, muscle [psoas major], abdominal fat) were flash 
frozen for vitamin E analysis. 
24-Hour urine and fecal collections - Cyp4f14
+/+ 
 and Cyp4f14
-/- 
 mice fed γT-10 or γT-
165 diets were placed in wire bottom polycarbonate metabolic cages in which urine and fecal 
pellets could be collected separately. Mice were afforded access to food and water, and 
collections were made over 24-h following a 24-h acclimation period. 
Cyp4f14 expression - Total RNA was extracted from flash frozen tissue liver samples 
(10-30 mg). Tissue samples were homogenized in 600 μL of RLT containing (1% v/v) β-
mercaptoethanol using a rotor-stator homogenizer. Homogenized samples were centrifuged at 
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10,000 rpm for 3 min to remove debris and the supernatants loaded onto QIAshredder spin 
columns followed by RNA isolation using the RNeasy Mini Kit, including an on-column DNA 
digestion step. RNA was reverse-transcribed using High Capacity cDNA Reverse Transcription 
Kit according to manufacturer’s instructions. The cDNA levels were detected using Taqman 
Universal Master Mix using Roche LightCycler 480 II with pre-designed TaqMan Assays for 
Cyp4f14 (Mm00491623_m1) and Cyp3all (Mm00731567_m1), using Eukaryotic 18s RNA 
(Hs99999901_s1) as the reference gene. Amplification conditions were as follows: 50˚C, 2 min; 
95˚C, 10 min (1 cycle); 95˚C, 15 s; 60˚C, 1 min (40 cycles); 37˚C, 10 s (1 cycle). The percent 
remaining expression of each target mRNA relative to 18s mRNA was calculated based on the 
threshold cycle (Ct) as 2
-Δ(ΔCt), where ΔCt = Cttarget-Ct18s and Δ(ΔCt) = ΔCthet–ΔCtwt or ΔCtko-
ΔCtwt. 
Microsomal vitamin E-ω-hydroxylase activity - Microsomal vitamin E-ω-hydroxylase 
activity was assayed using γ-TOH, δ-TOH, α-TOH, and γ-T3 as substrates complexed with BSA 
as described (7). The reaction system (0.5 ml) consisted of 0.1 M NaP buffer (containing 0.1 
mmol/L EDTA, pH 7.4), 1.0 mM NADPH and 25 ug microsomal protein. Substrate 
concentrations were 80 µmol/L δ-TOH, 80 µmol/L γ-TOH, 250 µmol/L α-TOH, and 20 µmol/L 
γ-T3 to account for differences in microsomal uptake of each form of vitamin E (15). Following 
incubation at 37˚C for 15 min and 30 min, hydroxylation products were extracted, derivatized, 
and quantitated by GC-MS as previously described (15), using d9-α-TOH as internal standard. 
Product formation for all substrates was linear over the 0 to 30 minute period, the slope of which 
was used to compare enzyme activity between treatments. 
Urine and fecal analysis of tocopherols and metabolites - 24-h urine and fecal samples 
from Cyp4f14
+/+ 
and Cyp4f14
-/- mice fed the γT-10 diet (n=4) and mice fed the γT-165 diet (n=6) 
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were incubated with β-glucuronidase (800 units for urine, 1600 units for feces dissolved in NaP 
buffer, pH 6.8) and sulfatase (0.4 units for urine, 0.8 units for feces) for 2 hours at 37˚C. Samples 
were acidified to pH 2 with 3 N hydrochloric acid (HCl), extracted with hexane-MTBE (3:1), 
and derivatized as above. Tocopherols and their metabolites were quantified by GC-MS using d9-
α-TOH and d9-α-CEHC as internal standards. 
Tocopherol quantification in tissue and plasma -  Solid tissue samples were 
homogenized in 1 ml 0.9% NaCl, 2 ml of isopropanol and 1 ml MTBE using a Polytron 
homogenizer, after which 3 ml hexane was added and the mixture shaken then centrifuged to 
separate organic and aqueous layers. The organic layer was evaporated to dryness using N2 gas 
and derivatized as described above. Plasma (40 μL) was extracted with 80 uL ethanol, 100 uL 
MTBE and 1 ml of hexane. Tocopherols were quantified using GC-MS with d9-α-TOH as 
internal standard. 
GC-MS quantification of tocopherols and metabolites - A Hewlett-Packard 6890 gas 
chromatograph (GC) coupled to a Hewlett-Packard 5872 mass selective  (MS) detector, operated 
in selected ion mode, was used for quantification of the various forms of vitamin E and their 
metabolites. The gas chromatograph was fitted with a Hewlett-Packard HP-1 methylsiloxane 
capillary column (30 m x 0.25 µm) and operated in split injection mode using helium as the 
carrier gas. Plasma tocopherols and microsomal ω-oxidation metabolites were resolved 
isothermally at 280˚C. Analysis of diet, tissue, and fecal tocopherols, and urinary and fecal 
tocopherol metabolites, was conducted using a temperature program of 200˚C for 2 min, ramped 
to 250˚C at 7˚C/min, held 6 min, then ramped to 280˚C at 25˚C/min, then held for 16 min. Novel 
11'-OH and 12'-OH metabolites of γ- and δ-TOH were identified by their mass spectra using the 
same temperature program with the instrument operated in scan mode. 
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Statistical analysis - A goodness of fit Chi Squared test was performed to test whether 
offspring of Cyp4f14
+/-
 breeding pairs were produced in a Mendelian ratio. For RT-PCR data, the 
average 18s-normalized threshold cycle (ΔCt) for each target gene was compared between the 
wild-type, heterozygote and knockout samples using Wilcoxon 2 group test, which yielded the 
estimation of ΔΔCt. Due to the small sample size, a non-parametric test followed by a 
Bonferonni correction for multiple comparisons was used to compare ΔΔCt between genotype 
groups. Microsomal enzyme activity data (pmol 13'-OH product/min/mg protein) and in vivo 
total ω-oxidation metabolite excretion (urine + fecal) were log transformed to meet the 
assumptions of the statistical tests used. Differences in enzyme activity and ω-oxidation 
metabolite excretion between genotypes were tested using 1-way ANOVA for each tocopherol 
substrate, with post hoc multiple comparison corrections using a Tukey’s correction.  
Mean percentage reductions in enzyme activity and total ω-oxidation metabolite 
excretion were calculated by comparing individual Cyp4f14
-/-
 values with the mean Cyp4f14
+/+
 
value. These percentage reductions were compared between each tocopherol substrate using a 
non-parametric Wilcoxon 2 group test, followed by Bonferonni correction for multiple 
comparisons. 24-h urine and fecal metabolite and tocopherol excretion data was log transformed 
as necessary. Means or transformed means were compared between genotypes using Student’s t-
test. As necessary, non-transformed data were compared using a non-parametric Wilcoxon 2-
group test. Plasma and tissue α-, γ-, and δ-TOH data were log transformed for comparison 
between genotypes using 1-way ANOVA, using Tukey’s post hoc multiple comparison 
correction when all three genotypes were compared. All tests were two-sided, and a p-value of 
<0.05 was considered statistically significant. Analyses were performed using JMP version 8 
(SAS Institute). 
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Results 
Identification of Cyp4f14 as a murine TOH-ω-hydroxylase - Treatment of mouse liver 
microsomes with anti-human CYP4F2 antibodies inhibited TOH-ω-hydroxylase activity by 94% 
compared to control (Fig. 1. 2A), indicating that virtually all TOH-ω-hydroxylase activity in 
mouse liver microsomes resulted from Cyp4f activity. An ortholog search revealed two murine 
proteins with >80% sequence identity to that of human CYP4F2 protein, namely Cyp4f15 and 
Cyp4f14. Both genes were reported to be expressed in murine liver (25). Therefore both genes 
were amplified from mouse liver cDNA, cloned into a mammalian expression vector, and 
transfected into COS-7 cells, that exhibit no detectable endogenous TOH-ω-hydroxylase activity. 
Cell-lines that stably express Cyp4f15 and Cyp4f14 were then selected and propagated. Anti- 
CYP4F2 Western blotting of the stably-transfected cells showed immunoreactive bands at the 
expected molecular weight of 58 kDa that was not observed in non-transfected controls (Fig. 
1.2B, insert). These data confirmed that the selected cell-lines expressed the two Cyp enzymes 
at similar levels. 
Membrane preparations from the stably-transfected cell lines were assayed for TOH-ω-
hydroxylase activity. Membranes from COS-7/Cyp4f14 cells exhibited robust TOH-ω-
hydroxylase activity whereas those prepared from COS-7/Cyp4f15 and non-transfected control 
cultures did not (Fig. 1.2B). In addition, ω-hydroxylase activity in COS-7/Cyp4f14 cultures 
exhibited a similar substrate selectivity (δ-TOH > γ-TOH > α-TOH) and inhibition by sesamin 
(data not shown) as human HepG2 and A549 cells, both of which express CYP4F2 and exhibit 
TOH-ω-hydroxylase activity (29, 30). Based on these findings, we concluded that Cyp4f14 is a 
murine TOH-ω-hydroxylase and proceeded to examine its function in vivo by targeted disruption 
of its expression in the mouse.  
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Figure 1.2. Evidence that Cyp4f14 is a functional murine vitamin E ω-
hydroxylase. A. Inhibition of mouse microsomal tocopherol-ω-hydroxylase 
activity by anti-4F antibody. Mouse liver microsomes were incubated with 
indicated concentrations of anti-human CYP4F2 IgG or pre-immune (control) IgG 
and 60 μM δ-TOH. Formation of 13'-OH-δ-TOH was quantified by GC-MS and 
normalized to microsomal protein content. B. Assessment of TOH-ω-
hydroxylase activity in COS-7 cell membranes. Total cell membrane 
preparations from COS-7 cells expressing Cyp4f14 or Cyp4f15 were incubated 
with 60 μM δ-TOH, and production of 13'-OH-δ-TOH quantified by GC-MS. The 
insert shows an anti-CYP4F2 Western blot of the two preparations and of 
untransfected control (NT). 
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Generation and Initial Characterization Cyp4f14-disrupted Mice – F1 Cyp4f14+/- mice 
were bred, generating a total of 90 F2 offspring whose genotype segregated in a Mendelian 
fashion (29% Cyp4f14
-/-
, 19% Cyp4f14
+/+
, 52% Cyp4f14
+/-
). Cyp4f14
-/-
 mice exhibited no overt 
anatomic abnormalities and body weights of the three genotypes were similar irrespective of age 
or diet. Expression analysis using RT-PCR confirmed the absence of Cyp4f14 mRNA in livers of 
Cyp4f14
-/-
 mice and 50% reduction in Cyp4f14
+/-
 mice (Fig. 1.3B). Hepatic expression of 
Cyp3a11 was similar between genotypes in both experimental diet groups (data not shown).  
 
 
 
 
 
 
 
 
 
Figure 1.3B. Relative Cyp4f14 mRNA in liver of Cyp4f14
+/+
, Cyp4f14
+/-
 and 
Cyp4f14
-/-
 mice. Cyp4f14 mRNA in Cyp4f14
+/-
 mice was approximately 50 
percent of wild-type mice and undetectable in Cyp4f14
-/-
 mice (p<0.05). 
 
Hepatic vitamin E-ω-hydroxylase activity in Cyp4f14-disrupted mice - Hepatic 
microsomal vitamin E-ω-hydroxylase activity in mice fed the γT-10 diet was substantially 
reduced in Cyp4f14
-/-
 mice relative to Cyp4f14
+/+
 mice. The extent of reduction varied among 
tocopherol substrates, with the largest reduction seen with γ-TOH (93%); activity  
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Figure 1.4.  Impact of Cyp4f14 disruption on liver microsomal vitamin E-ω-hydroxylase 
activity and on whole body excretion of ω-oxidation metabolites (urine + fecal). A. Mouse 
liver microsomes from wild-type (solid bar) and Cyp4f14
-/-
 (open bar) mice fed γT-165 diet were 
incubated with indicated tocopherol substrates (250 μmol/L α-TOH, 80 μmol/L γ- and δ-TOH) 
and the corresponding 13'-OH metabolites quantified by GC-MS. Values are percentage of wild-
type preparations (n=6). Wild-type activity was 21.0±1.64, 88.1±7.20, and 161.2±11.7 pmol 13'-
OH product/min/mg protein toward α-TOH, γ-TOH, and δ-TOH, respectively. Reduction in 
activity was substrate dependent, with the greatest impact (>90%) on ω-hydroxylation of γ-TOH. 
Asterisks indicate significant differences from wild-type; different letters indicate significant 
differences in percent reduction between substrates (p<0.05). B. 24-Hour urinary plus fecal 
excretion of total ω-oxidation metabolites (13'-OH, 13'-COOH, and all chain shortened forms) 
was quantified by GC-MS. Metabolite levels are expressed as percentages of values observed in 
wild-type mice (n=6). Asterisks represent significant differences from wild-type; different letters 
indicate significant differences in percent reduction between substrates (p<0.05). Wild-type ω-
hydroxy metabolite excretion was 0.39±0.10, 109.3±8.82, and 62.5±7.99 nmol/24-hr toward α-
TOH, γ-TOH, and δ-TOH, respectively. The pattern of substrate-dependent impact of Cyp4f14 
disruption was similar to that observed in microsomes (A). 
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toward α- and δ-TOH was 66 and 63% reduced, respectively. ω-Hydroxylation of γ-T3 was 
reduced by 48% in Cyp4f14
-/- 
mice, and reductions in activity in Cyp4f14
+/- 
mice were 
approximately half that of Cyp4f14
-/-
 mice (data not shown). Similar results were obtained using 
microsomes from livers of mice fed the γT-165 diet (Fig. 1.4A).  
Effect of Cyp4f14 disruption on urinary and fecal excretion of TOH-ω-oxidation 
metabolites - Metabolic cages were utilized to obtain 24-h urine and fecal samples from 
Cyp4f14
+/+
 and Cyp4f14
-/-
 mice. In urine, only short chain metabolites (3'- and 5'-
carboxychromanols) of dietary tocopherols were detected. In mice fed the γT-165 diet, urinary 
excretion of these two γ-TOH metabolites was reduced by about 90% in Cyp4f14-/- mice relative 
to their wild-type counterparts (Table 1.2). Smaller but still significant reductions in urinary 
output of short chain metabolites of α- and δ-TOH were observed in the Cyp4f14-/- mice. Similar 
results were obtained from mice on the γT-10 diet (data not shown). 
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Analysis of 24-h fecal samples revealed the presence of all six possible 
carboxychromanol metabolites and the 13'-OH metabolites of γ- and δ-TOH formed via the ω-
oxidation pathway in mice fed the γT-165 diet. Disruption of Cyp4f14 expression resulted in 
significant reductions in all seven ω-oxidation metabolites of γ-TOH and the reduction of many 
δ-TOH metabolites (Table 1.3). Fecal levels of δ- and γ-TOH metabolites from mice fed the γT-
10 diet were low and similar among genotypes (data not shown). The 13'-OH metabolite of α-
TOH was the only appreciable α-TOH metabolite in the feces of both diet groups, and was 
found at trace concentrations in both genotypes (data not shown).  
Whole body 24-h excretion of total tocopherol metabolites generated via the ω-oxidation 
pathway (urinary plus fecal) in Cyp4f14
+/+
 and Cyp4f14
-/-
 mice fed the γT-165 diet was 
calculated. Excretion of ω-oxidation metabolites of the three dietary tocopherols by Cyp4f14-/- 
mice was reduced to approximately the same extents (88, 72, and 65%, respectively for γ-, δ-, 
and α-TOH) as those observed in the in vitro ω-hydroxylation assays (Fig. 1.4A-B). 
Fecal excretion of novel ω-1 and ω-2 hydroxylation products of γ- and δ-TOH - Two 
metabolites not previously reported to occur in vivo, 12'-OH and 11'-OH oxidation products of 
γ- and δ-TOH, were also observed in fecal samples. The structures of these metabolites were 
determined by mass spectrometry analysis (Fig. 1.5). These represent products of ω-1 and ω-2 
hydroxylation activities, respectively. 12'-OH-γ-TOH was the most abundant γ-TOH metabolite 
in fecal samples of Cyp4f14
-/-
 mice fed the γT-165 diet, representing approximately 80% of total 
fecal γ-TOH metabolites, and was the second most abundant of all excreted  γ-TOH metabolites 
in Cyp4f14
+/+
 mice. Interestingly, fecal excretion of 12'-OH-γ-TOH was significantly greater in 
Cyp4f14
-/-
 mice (41.3±9.1 nmol/day) than in Cyp4f14
+/+
 mice (7.6±2.3 nmol/day, Table 1.3). 
Consequently, 24-h fecal output of total metabolites (sum of ω, ω-1, ω-2 metabolites of α-, γ-,  
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Figure 1.5. Mass spectra of novel fecal ω-1 and ω-2 hydroxy tocopherol 
metabolites. Lipid extracts of 24-h fecal samples from mice fed a soybean oil diet 
were derivatized and subjected to electron impact GC-MS analysis. Upper panel: 
11'-OH-γ-tocopherol (trimethylsilyl derivative). Lower panel: 12'-OH-γ-
tocopherol (trimethylsilyl derivative). 
 
and δ-TOHs) was reduced by only 34% in Cyp4f14-/- mice fed the γT-165 diet relative to 
Cyp4f14
+/+
 mice, while the analogous reduction in total urinary metabolites (3'- and 5'-COOH 
metabolites only) was 81% (Fig. 1.6A). In contrast, the excretion of the ω-1 and ω-2 
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metabolites of δ-TOH was not significantly increased in Cyp4f14-/- mice compared to 
Cyp4f14
+/+
 mice (Fig. 1.6B). 
Fecal excretion of parent tocopherols in Cyp4f14
+/+
 and Cyp4f14
-/-
 mice - 
Unmetabolized tocopherols were present in all 24-h fecal samples. In mice fed the γT-165 diet 
for six weeks, 24-h fecal tocopherol excretion was in the order of γ-TOH>δ-TOH>α-TOH, 
similar to their prevalence in the diet (Table 1.1). Fecal excretion of γ- and δ-TOHs by Cyp4f14-
/-
 mice was approximately twice that of Cyp4f14
+/+
 mice (p<0.05, Fig. 1.6B). Fecal excretion of 
γ-TOH increased from 137 nmol/24-h in wild-type mice to 239 nmol/24-h in Cyp4f14-/- mice. 
The analogous values for δ-TOH were 32 and 63 nmol/24-h in wild-type and Cyp4f14-/- mice, 
respectively. 
Effect of Cyp4f14 disruption on plasma and tissue tocopherol concentrations - In 
Cyp4f14
-/-
 mice fed the γT-165 diet for six weeks, concentrations of γ-TOH in plasma and 
tissues were approximately twice those of Cyp4f14
+/+
 mice (Fig. 1.6C). In the liver, 
concentrations of γ-TOH were similar, or in some mice higher, than those of α-TOH. 
Concentrations of δ-TOH were significantly elevated only in fat tissue, and those of α-TOH 
were significantly lower in heart tissue (Table 1.4). In Cyp4f14
-/-
 mice fed the γT-10, liver γ-
TOH concentrations, while low, were double those of Cyp4f14
+/+
 mice (p<0.05); there were no 
differences between genotypes of concentrations of any tocopherol in other tissues (data not 
shown). 
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Figure 1.6. Impact of Cyp4f14 disruption on whole-body TOH metabolism and on concentrations of γ-TOH in plasma and 
tissues. A. Metabolites of γ-TOH in 24-h urine and fecal collections from wild-type mice (solid bar) and Cyp4f14-/- mice (open bar) 
were quantified by GC-MS. Asterisks indicate significant differences from wild-type mice. B. Change (nmol) from wild-type mice to 
Cyp4f14
-/-
 mice in 24 hr urinary and fecal excretion of metabolites of γ-TOH (solid bar) and δ-TOH (hatched bar), or the parent 
tocopherols. Cyp4f14
-/-
 mice counterbalance the loss of ω-oxidation capacity by increased fecal excretion of 11'-OH- and 12'-OH 
metabolites and parent tocopherols. C. Concentration of γ-TOH in plasma and tissues of wild-type (solid bar) and Cyp4f14-/- mice 
(open bar) fed the γT-165 (soybean oil) diet for 6 wks. Insert compares tocopherol composition of liver of wild-type and Cyp4f14-null 
mice. Asterisks indicate significant differences from wild-type mice (p<0.05).
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Discussion 
Tocopherols and tocotrienols undergo ω-hydroxylation at the terminal methyl groups of 
their hydrophobic side chains, the first step in their catabolism to short chain 
carboxychromanols that are excreted in the urine. In the human, TOH-ω-hydroxylation is 
catalyzed by CYP4F2, which selectively catabolizes forms of vitamin E other than α-TOH. The 
ω-hydroxylation pathway therefore likely contributes to the α-TOH phenotype, a highly 
conserved trait in animals. The preferential retention of α-TOH additionally arises from the 
selection of α-TOH by the tocopherol transfer protein, the absence of which results in severe 
vitamin E deficiency (7, 31). As all forms of vitamin E exhibit similar radical trapping 
antioxidant activity in vitro (2), the evolutionary  advantage of the preferential accumulation of 
α-TOH and the physiological consequences of accumulation of other forms of vitamin E are 
unknown. In an effort to investigate these issues, we sought to identify the functional murine 
ortholog of CYP4F2 and determine the consequences of its deletion on vitamin E metabolism 
and status. 
Cyp4f14, one of 5 functional murine Cyp4f enzymes, exhibited vitamin E-ω-
hydroxylase activity when expressed in COS-7 cells. Like CYP4F2, Cyp4f14 is expressed 
predominantly in the liver. Cyp4f15, a highly homologous murine Cyp also expressed in liver, 
had no detectable ω-hydroxylase activity. Disruption of Cyp4f14 by homologous recombination 
substantially reduced, but did not eliminate, vitamin E-ω-hydroxylase activity in murine liver 
microsomes. The reduction in activity was substrate dependent, being greatest for γ-TOH (92 
percent). These results indicate that at least one other vitamin E-ω-hydroxylase is expressed in 
the mouse liver. Plasma and tissue tocopherol concentrations in Cyp4f14
-/-
 mice fed a diet low in 
γ- and δ-TOH was similar to those of wild-type mice except for the liver, where γ-TOH levels 
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were slightly but significantly elevated. However, in mice fed a diet rich in γ-TOH (soybean 
oil), the metabolic deficit caused by Cyp4f14 deletion resulted in substantial elevation (2-fold) 
of γ-TOH concentrations in all tissues and in plasma. Notably, concentrations of γ-TOH in the 
liver were similar to or higher than those of α-TOH thereby disrupting the α-TOH phenotype in 
this tissue. Tissue and plasma levels of δ-TOH remained low and unchanged, presumably due to 
residual δ-TOH-ω-hydroxylase activity sufficient to catabolize the modest amount of δ-TOH in 
the diet. Accumulation of γ-TOH in Cyp4f14-/- mice did not result in any apparent 
physiologically abnormal phenotype. A 2-3 fold increase in tissue γ-TOH levels significantly 
reduced protein nitration and ascorbic acid oxidation in an experimental model of inflammation 
(32). Therefore, a model in which non-α-TOH forms of vitamin E accumulate to a greater 
degree than normal will allow for the investigation of the biological activities of these 
compounds in regards to disease development, prevention and treatment. 
The impact of Cyp4f14 disruption on whole-body tocopherol metabolism was 
investigated by analysis of 24-h urine and fecal samples. Urine contained only the shortest chain 
(3' and 5') carboxychromanol metabolites, while the feces contained the full spectrum of known 
metabolites of δ- and γ-TOHs formed via the ω-oxidation pathway, with the longer chain 
metabolites predominating. These results demonstrate that short chain carboxychromanols are 
directed to secretion from the liver into the bloodstream and filtered by the kidney, while the 
longer, more hydrophobic metabolites are directed to biliary secretion and excretion via the 
feces. One major impact of Cyp4f14 disruption was to dramatically alter the proportion of total 
metabolites excreted via urinary versus fecal routes. In wild-type  mice, 60 percent of total 
metabolite output was eliminated via the feces, while in Cyp4f14
-/-
 mice , in which urinary short 
chain carboxychromanols were drastically reduced, this proportion rose to 85 percent.  
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Novel ω-1 (12') and ω-2 (11') hydroxyl metabolites of δ- and γ-TOH were identified in 
fecal pellets of mice fed the γT-165 diet. These apparently arise in liver and are secreted in bile, 
as they were detected in the few bile samples able to be obtained from animals fed this diet 
(data not shown). The 12'-OH metabolite is a terminal metabolite in that it cannot undergo 
oxidation to the corresponding 12'-keto form, therefore cannot undergo side chain truncation. 
The metabolic fate of the 11'-OH form remains uncertain. Since we have been unable to confirm 
the presence of the corresponding 11'-keto form, we assume that it does not materially 
contribute to the formation of shorter chain carboxychromanols excreted in either feces or urine. 
Formation of these novel metabolites constituted a significant alternative pathway of 
metabolism of γ- and δ-TOHs, increasing from 30 percent of total fecal metabolites in wild-type 
mice to 80 percent in Cyp4f14-null mice.  
Fecal excretion of 11'-OH and 12'-OH metabolites of γ- TOH was increased 
substantially in Cyp4f14
-/-
 mice, thereby partially counterbalancing the loss of Cyp4f14 activity. 
This additionally contributed to the impact of Cyp4f14 disruption on the shift of tocopherol 
metabolite excretion from the urinary route to the fecal route, and from short chain metabolites 
to longer chain metabolites. At present it is not known whether the increase in excretion of these 
ω-1 and ω-2 metabolites resulted from increased activity of a yet unidentified enzyme, or from 
increased availability of substrate secondary to the loss of Cyp4f14. This increase apparently 
did not involve the induction of Cyp3a11 since its expression was not altered by disruption of 
Cyp4f14. Cyp4f14
-/- 
mice also exhibited increased fecal excretion of parent δ- and γ-TOHs, 
representing a second means of counterbalancing for the decrement in catabolic capacity. 
Whether this results from decreased intestinal absorption or increased biliary secretion of 
tocopherols is unknown as few animals presented with sufficient gall bladder bile for collection. 
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Nevertheless, the combination of these counterbalancing effects was insufficient to prevent 
substantial tissue accumulation of γ-TOH in mice fed the soybean oil diet.  
Given the importance of α-TTP in the trafficking of α-TOH in the liver, we quantified α-
TTP expression by Western blotting as a function of both diet and genetic background. α-TTP 
was visualized by Western blotting using a rabbit polyclonal antibody raised against the full-
length human protein, purified from over-expressing E. coli. Neither variable influenced hepatic 
α-TTP expression (data not shown). 
These studies revealed the heretofore unappreciated quantitative importance of fecal 
excretion of tocopherols and tocopherol metabolites as a mechanism for preventing elevation of 
tocopherol concentrations in serum and tissues. In wild-type mice, up to 80 percent of whole 
body output of vitamin E (sum of intact tocopherols and their metabolites) occurred via the 
feces. This value rose to 96 percent in the Cyp4f14-null animals. While Zhao et al (33)  reported 
the existence of many tocopherol metabolites in feces, to our knowledge there are no reports of 
the quantitative contribution of the fecal route to vitamin E status. In addition to the novel ω-1 
and ω-2 metabolites reported here, this is the first report of the presence of significant amounts 
of 13'-OH tocopherol metabolites in feces. How these latter metabolites escape further side 
chain oxidation is unclear, but suggests that yet-unknown mechanisms are present in the liver 
that direct these long chain metabolites to biliary secretion. 
These studies investigated the effects of Cyp4f14 deletion on vitamin E metabolism from 
two perspectives:  in vitro liver microsomal P450-mediated tocopherol hydroxylation and in 
vivo metabolic capacity as measured by 24-h excretion of tocopherol metabolites in urine and 
feces. The substrate-dependent decrement resulting from Cyp4f14 deletion was remarkably 
similar between microsomal and whole-body measurements of tocopherol ω-oxidation (Fig. 
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2.4). This observation indicates that the liver plays a pivotal role in whole-body vitamin E ω-
oxidation that can be qualitatively predicted by microsomal ω-hydroxylation activity. 
Interestingly, only small amounts of the 12'-OH metabolites of γ- and δ-TOHs were produced in 
the microsomal system (data not shown), while they comprised a major fraction of tocopherol 
metabolites in vivo. The reason for this discrepancy is presently unknown.  
It is unknown whether the redundancy in the catabolic oxidation of vitamin E evident in 
mice also exists in humans. The human CYP3A4 has been hypothesized to be involved in 
vitamin E metabolism based on the finding that supplemental dietary α-TOH in mice leads to 
increased mRNA expression of its putative ortholog, Cyp3a11, but not that of mouse Cyp4f 
enzymes (34). However,  evaluation of all of the major human liver CYP enzymes, including 
CYP3A4,  showed that CYP4F2 was the only CYP enzyme to exhibit ω-hydroxylase activity 
toward vitamin E (18). Additionally, conditions expected to alter CYP4F2 activity result in 
changes in vitamin E status. For example, short term ingestion of sesame seeds, which contain 
sesamin, an inhibitor of CYP4F2 (35), results in elevation of serum γ-TOH (36). A recent 
genome-wide association study reported that the V433M variant of CYP4F2 was positively 
associated with plasma vitamin E concentration (37). We previously reported that this variant 
exhibited a reduction in enzyme specific activity by 40-60 percent depending on substrate (38). 
Our heterozygous mice, which display a 50 percent reduction in vitamin E-ω-hydroxylase 
activity, exhibit a 50 percent increase in tissue γ-TOH concentrations. Taken together, these 
findings suggest the importance of CYP4F2 as a major regulator of vitamin E composition of 
human plasma and tissues. 
In summary, our data demonstrate that Cyp4f14 is the major, but not the only, vitamin 
E-ω-hydroxylase in mice, and has critical function in regulating body-wide vitamin E status. 
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Disruption of Cyp4f14 expression resulted in hyper-accumulation of γ-TOH in plasma and 
tissues in mice fed a diet similar in tocopherol composition to that consumed by many human 
populations. This accumulation occurred despite the combined counterbalancing effects of 
increased fecal excretion of novel ω-1 and ω-2 tocopherol oxidation metabolites and increased 
fecal excretion of parent tocopherols. Redundancy in vitamin E-ω-hydroxylase activity and the 
existence of counterbalancing mechanisms implies a fundamental biological advantage of the α-
TOH phenotype that remains elusive. 
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CHAPTER 2 
DISRUPTION OF P450-MEDIATED VITAMIN E HYDROXYLASE ACTIVITIES ALTER 
VITAMIN E STATUS IN TOCOPHEROL SUPPLEMENTED MICE AND REVEAL EXTRA-
HEPATIC VITAMIN E METABOLISM 
Introduction  
Vitamin E, a family of plant-derived lipophilic compounds, consists of tocopherols 
(TOHs) and tocotrienols (T3s), and is considered to be the most important group of lipophilic 
antioxidants.  These structurally related compounds differ only in the number and placement of 
methyl groups on the polar head of the molecule and in the presence of double bonds in the side 
chain.  Interestingly, while the typical American diet contains 2-4 times as much γ-TOH as α-
TOH (4, 5), α-TOH is present in the serum and tissues at levels 5-6 times that of γ-TOH (6).  
This preferential accumulation of α-TOH in tissues, termed the α-TOH phenotype, is widespread 
in the animal kingdom and occurs despite the fact that all forms of vitamin E exhibit roughly 
similar radical scavenging activities (2, 3).  While in vitro and animal studies have suggested 
both beneficial and detrimental biological actions of non-α-TOH forms of vitamin E, the 
biological advantage of the α-TOH phenotype remains elusive. 
The cytochrome P450 (CYP) superfamily of enzymes catalyze a vast number of catalytic 
reactions, including the metabolism of lipids, steroids, and xenobiotics.  These endoplasmic 
reticulum-bound enzymes require NADPH and the co-enzyme cytochrome P450 reductase 
(CPR) for the source and transfer of electrons to the CYP enzyme.  We previously identified 
cytochrome P450 4F2 (CYP4F2) as a human vitamin E-ω-hydroxylase (18), catalyzing the 
hydroxylation of one of the terminal methyl groups of the hydrophobic side chain.   This ω-
hydroxylation can be followed by oxidation to the corresponding carboxyl form, and a series of 
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side-chain shortening steps ultimately leading to the formation of the 3' and 5' carboxychromanol 
metabolites that can be excreted in the urine (19-21).  CYP4F2 displays substrate preference, 
such that non-α-TOH forms of vitamin E are metabolized to a greater extent than α-TOH, 
thereby contributing to the α-TOH phenotype (15). 
Using a novel Cyp4f14 knockout mouse model, we have recently identified CYP4F14 as 
the major mouse vitamin E-ω-hydroxylase, accounting for 70-90% of whole-body ω-hydroxy 
metabolite production (39).  This result demonstrated the existence of other vitamin E-ω-
hydroxylase enzyme(s) in the mouse. In addition, two novel metabolites were discovered: 12'- 
and 11'-OH fecal metabolites of δ- and γ-TOH, which are products of ω-1 and ω-2 hydroxylation 
activities.  Interestingly, Cyp4f14
-/-
 mice display increased fecal excretion of these novel 
metabolites as well as increased fecal excretion of unmetabolized TOHs.  Despite these 
counterbalancing effects and redundancy in the TOH-ω-hydroxylase pathway, Cyp4f14-null 
mice fed a modest amount of γ-TOH in the form of soybean oil accumulated 2-fold more γ-TOH 
than wild-type mice.  While the urine has been commonly believed to be the site of TOH 
metabolites, we found the feces to be the predominant route of metabolite excretion.   
The aim of the current work was to investigate whether dietary supplementation with 
high levels of γ- and δ-TOHs would overcome the counterbalancing effects and result in tissue 
enrichment above that seen with the previous soybean oil diet.  Two experimental models were 
employed.  Firstly, we hypothesized that supplementation with elevated levels γ- and δ-TOH 
would exacerbate the effect of Cyp4f14 disruption on the tissue accumulation of those TOHs.  
Secondly, we hypothesized that γ- and δ-TOH supplementation in mice lacking liver-CPR, and 
therefore all hepatic TOH-hydroxylase activity, would hyper-accumulate TOHs to a greater 
extent than Cyp4f14
-/-
 mice.  This model also allowed for the opportunity to determine whether 
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tissues other than the liver possess this activity.  Additionally, we extended the previous findings 
concerning novel hydroxylase activities to determine their relevance in humans.  
 
Experimental Procedures 
Materials  - Modified AIN-93G rodent diets were manufactured by DYETS (Bethlehem, 
PA).  Tocopherols were obtained from Matreya, LLC (Pleasant Gap, PA).  Bovine serum 
albumin, NADPH, β-glucuronidase (from Escherichia coli), and sulfatase (from Aerobacter 
aerogenes), protease inhibitor cocktail (catalog number P2714), PMSF, EDTA, and glycerol 
were purchased from Sigma-Aldrich (St. Louis, MO).  Pooled human liver microsomes and 
pooled human small intestine mucosal microsomes were purchased from BD Biosciences (San 
Jose, CA).  The internal standards d9-α-TOH and d9-α-CEHC were custom synthesized by J. 
Swanson (Cornell University, Ithaca, NY). 
Tocopherol metabolism and tissue accumulation in Cyp4f14
-/-
 mice supplemented 
with γ- and δ-TOHs - Cyp4f14-/- mice, which are viable and fertile, and their wild-type 
littermates, were generated as described previously (39).  At 21 days of age, six mice of each 
genotype (3 male and 3 female) were weaned onto a modified AIN-93G semipufied diet 
containing 12 mg/kg α-TOH and supplemented with 800 mg/kg each δ-TOH and γ-TOH.  After 
12 weeks, 24-hr urine and fecal collections were made as described below.  Mice were deeply 
anesthetized by isoflurane inhalation and exsanguinated via cardiac puncture.  If bile was present 
in the gallbladder, it was collected with a syringe and frozen at -80°C until analysis.  Heparinized 
blood was centrifuged at 6,000 x g for 5 min, and serum frozen at -80°C until analysis.  Liver, 
kidney, lung, heart, abdominal fat, and brain tissue samples were flash frozen in liquid nitrogen 
for vitamin E quantification by GC-MS as described previously (39).  
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Tocopherol metabolism and tissue accumulation in liver-specific Cpr
-/-
 mice 
supplemented with γ- and δ-TOHs - L-Cpr-/-mice, which have trace liver CYP activity by 2 
months of age, and their wild-type littermates, were generated as described previously (40).  At 
2.5 month of age, four male mice of each genotype were fed a modified AIN-93G semipurified 
diet containing 12 mg/kg α-TOH and supplemented with 800 mg/kg each δ-TOH and γ-TOH.  
After 4 weeks, 24-hr urine and fecal collections were made as described below.  Mice were then 
euthanized and plasma and several tissues were collected as described above.  Approximately 0.6 
g of fresh liver was immediately used for preparation of microsomes as described below. 
24-Hour urine and fecal collections - Mice were placed individually in wire bottom 
polycarbonate cages in which urine and fecal pellets were collected separately.  Mice were 
afforded access to food and water, and collections were made over 24-hr following a 24-hr 
acclimation period. 
Liver microsome preparation – Microsomes were prepared from fresh mouse liver by 
standard differential centrifugation as previously described, resuspended in 0.1 M sodium 
phosphate (NaP) buffer containing 1 mM EDTA and frozen at -80˚C (39).  Microsomal protein 
concentrations were determined by a Bradford-based Bio-Rad assay using bovine serum albumin 
(BSA) as the standard.   
Intestinal mucosa microsome preparation – Mice were euthanized by isoflurane 
exposure, and upper 12 cm of the small intestine was immediately excised and placed on an ice 
cold sheet of glass.  The removed piece was immediately flushed with ice cold wash buffer 
(0.9% NaCl containing 1 mM EDTA and 1 mM PMSF), then cut longitudinally, opened, and 
rinsed with ice cold wash buffer to remove intestinal contents.  The mucosal cells were gently 
scraped off with a razor blade.  The intestinal mucosal cells were homogenized using a 
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Teflon/glass homogenizer with ice cold homogenization buffer (50 mM tris-HCl, pH = 7.4 
containing 150 mM KCl, 1 mM EDTA, 20% glycerol, 1 mM PMSF, and 10% protease inhibitor 
cocktail) and centrifuged at 10,000 x g for 20 min at 4°C.  The supernatant was centrifuged at 
100,000 x g for 1 h at 4°C.  The microsomal pellet was resuspended in 0.1 M NaP buffer 
containing 1 mM EDTA and frozen at -80˚C.  Microsomal protein concentration was determined 
by a Bradford-based Bio-Rad assay.    
Microsomal vitamin-E-ω-hydroxylase activity in L-Cpr+/+ and L-Cpr-/- – Microsomes 
from mouse liver and small intestine mucosa were assayed for ω-hydroxylase activity using γ-
TOH, δ-TOH, and α-TOH as substrates complexed with BSA as described (15).  The reaction 
system (0.5 mL) consisted of 0.1 M NaP buffer (pH=7.4), 1.0 mM NADPH and 100 µg 
microsomal protein.  Substrate concentrations were 80 µmol/L for γ- and δ-TOH and 250 
µmol/L for α-TOH to account for differences in microsomal uptake of each form of vitamin E 
(15).  Following incubation at 37°C for 1 h, hydroxylation products were extracted, derivatized, 
and quantified by GC-MS as previously described (15), using d9-α-TOH as internal standard. 
Analysis of TOHs and metabolites in 24-hr urine and fecal samples – 24-hr fecal 
collections were homogenized in PBS and an aliquot was used for analysis.  Urine and fecal 
samples were incubated with β-glucuronidase (800 units for urine or 1600 units for feces, 
dissolved in NaP buffer, pH 6.8) and sulfatase (0.4 units for urine or 0.8 units for feces) for 2 
hours at 37°C.  Samples were acidified to pH 2, extracted, and derivatized as previously 
described (39).  TOHs and their metabolites were quantified by GC-MS using d9-α-TOH and d9-
α-CEHC as internal standards. 
Analysis of bile TOHs and metabolites in Cyp4f14
+/+
 and Cyp4f14
-/-
 mice - Bile 
samples from Cyp4f14 mice (2 wild-type and 3 knockout) were incubated with enzymes (800 
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units β-glucuronidase, 0.4 units sulfatase) for 2 hours at 37°C.  Samples were then acidified and 
extracted as described above for urine. 
Detection of TOH metabolites in human fecal material – Reference fecal material was 
obtained from an individual following 7 days supplementation of either γ-TOH or α-TOH (400 
mg/kg/day).  Fecal materials were processed and analyzed for TOH metabolites as described 
above for mouse fecal samples. 
Vitamin E-ω-hydroxylase activity of human liver and intestinal microsomes – 
Pooled human liver microsomes (HLM) and pooled human intestinal mucosa microsmes (HIM) 
assayed for vitamin E-ω-hydroxylase activity using γ-TOH (80 μM), δ-TOH (80μM) and α-TOH 
(250μM) as substrates.  The reaction system (0.5 mL) consisted of 0.1 M NaP buffer containing 
0.1 mM EDTA, pH 7.4, 2.0 mM NADPH and 200 μg microsomal protein.  Following incubation 
at 37°C for 1 hr, reaction products were extracted, derivatized, and quantified by GC-MS as 
described above. 
Statistical Analysis - All tocopherols and tocopherol metabolites were log transformed 
as necessary and means were compared between wild-type and knockout mice using Student’s t-
test.  Additionally, tissue TOH concentrations in Cyp4f14
-/-
 mice were compared using a two-
way ANOVA with genotype and gender as main effects, as well as the interaction effect.  When 
the interaction effect was not significant, it was removed from the model.  All tests were two-
sided, and a p-value of <0.05 was considered statistically significant.  Analyses were performed 
using JMP version 8 (SAS Institute). 
Results 
Effect of Cyp4f14 disruption on 24-hr TOH and TOH metabolite excretion – 
Metabolic cages were utilized to obtain 24-hr urine and fecal samples from Cyp4f14
+/+
 and 
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Cyp4f14
-/-
 mice fed 800mg/kg of both δ- and γ-TOH for 12 weeks.  In urine, only 3'- and 5'-
carboxychromanol metabolites of δ- and γ-TOH were detected. Urinary metabolites of γ-TOH 
were reduced by 88% and those of δ-TOH were reduced by 77% in Cyp4f14-/- mice compared to 
their wild-type littermates.  Total urinary tocopherol metabolites were reduced by 82% in 
Cyp4f14
-/-
 mice (Table 2.1).   
 
 
 
 
 
 
 
 
 
 
Analysis of 24-hr fecal samples revealed the presence of all six carboxychromanol 
metabolites, as well as the 13'-OH metabolites of γ- and δ-TOH, formed via the ω-oxidation 
pathway (Table 2.2).  The 13'-COOH metabolite was consistently the predominant ω-oxidation 
metabolite in fecal samples.  Total ω-oxidation metabolites of γ-TOH were reduced by 79% and 
those of δ-TOH by 89% in Cyp4f14-/- mice.  12'-OH and 11'-OH metabolites of γ- and δ-TOH 
were also present, formed via the ω-1 and ω-2 oxidation pathways, respectively.  These 
metabolites were also detected in the limited number of gallbladder bile samples that were 
collected (data not shown).
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24-Hr whole body (urine + fecal) ω-oxidation metabolites of γ- and δ-TOH were reduced 
by 82% in Cyp4f14
-/-
 compared to wild-type mice (Fig. 2.1A).  The sum of 24-hr ω-1 and ω-2 
metabolites of γ- and δ-TOH, while numerically higher in Cyp4f14-/- mice (30%), was not 
statistically altered by the disruption of Cyp4f14.  As a result, the combination of metabolites 
from all three pathways was 40% reduced in Cyp4f14
-/-
 mice.  24-Hr fecal excretion of 
unmetabolized TOHs was not statistically different between wild-type and Cyp4f14-null mice 
(Fig. 2.1B). 
Tissue TOH status of Cyp4f14
+/+
 and Cyp4f14
-/- 
supplemented with γ- and δ-TOHs  – 
Cyp4f14
-/- mice displayed significantly higher tissue concentrations of  δ-TOH in the plasma, 
lung, and liver averaging a 70% increase in these tissues compared to wild-type mice.  Cyp4f14
-/-
 
mice also had significantly higher γ-TOH in the plasma, lung, kidney, liver and brain, averaging 
a 90% increase in these tissues compared to wild-type mice (Fig. 2.1C).  The tissues with the 
largest difference from wild-type mice were plasma for δ-TOH (2.2-fold higher than wild-type) 
and brain for γ-TOH (2.7-fold higher than wild-type).  A gender effect was observed for many 
forms of vitamin E such that females had significantly higher levels of TOHs in several tissues.  
These gender differences were observed in the plasma (γ-, δ-TOH), lung (α-, γ-, δ-TOH), kidney 
(γ-, δ-TOH), liver (α-, γ-, δ-TOH), heart (α-TOH), brain (α-, γ-, δ-TOH), and fat (δ-TOH).  
Except for δ-TOH in the plasma, the interaction effect was not significant, indicating the effect 
Cyp4f14 disruption on tissue TOH concentration did not differ by gender. 
Effect of liver-specific Cpr disruption on liver microsomal TOH-ω-hydroxylase 
activity and TOH metabolism and excretion – Wild-type mice displayed robust hepatic 
microsomal ω-hydroxylase activity toward γ-TOH (101 pmol product/min/mg protein ) and δ-
TOH (125 pmol product/min/mg protein).  L-Cpr-null mice exhibited no detectable ω-  
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Figure 2.1. Effect of Cyp4f14 disruption on vitamin E metabolism and tissue accumulation 
in mice supplemented with γ- and δ-TOH for 12 weeks.  A. 24-Hr ω-hydroxy, ω-1/ω-2 
hydroxy and total vitamin E metabolite excretion in wild-type (solid bar) and Cyp4f14
-/-
 mice 
(open bar) were quantified by GC-MS.  Asterisks indicate significant differences from wild-type.  
B. 24-Hr fecal excretion of unmetabolized TOH in wild-type (solid bar) and Cyp4f14
-/-
 mice 
(open bar).  C. Concentration of TOHs in plasma and tissues of wild-type (solid bar) and 
Cyp4f14
-/-
 mice (open bar) fed the supplemented diet for 12 weeks.  Asterisks indicate significant 
differences from wild-type mice (p<0.05).   
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hydroxylase activity towards either substrate.  Urinary metabolites (3'- and 5'-
carboxychromanols) of γ-TOH were reduced by 56% and those of δ-TOH were reduced by 72% 
in L-Cpr
-/-
 mice compared to their wild-type littermates.  Total urinary tocopherol metabolites 
(sum of γ- and δ-TOH metabolites) were reduced by 70% in L-Cpr-/- mice (Table 2.3). Mice of 
both genotypes excreted substantially more metabolites of δ-TOH than γ-TOH, despite their 
similar concentration in the diet.  Analysis of 24-hr fecal samples revealed the presence of all 
previously identified ω-0, ω-1 and ω-2 metabolites of γ- and δ-TOH except 7'-COOH-γ-TOH 
(Table 2.4).   As was the case with Cyp4f14 mice, the 13'-COOH was the predominant ω-
oxidation metabolite in fecal samples. 24-Hr whole body (urine + fecal) ω-oxidation metabolites 
of γ- and δ-TOH were reduced by 70% in in L-Cpr-/- mice compared to wild-type mice while ω-1 
and ω-2 metabolites were unchanged (Fig. 2.2A).  The sum of metabolites of both TOHs from 
all three pathways were 66% lower in L-Cpr-null mice.  Fecal excretion of unmetabolized TOHs 
was greater in L-Cpr
-/-
 mice compared to wild-type mice for α-TOH (2.4-fold), γ-TOH (3.2-
fold), and δ-TOH (6.6-fold; Fig. 2.2B).   
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Figure 2.2. Effect of the L-Cpr disruption on vitamin E metabolism and tissue 
accumulation in mice supplement with γ- and δ-TOH for 4 weeks A. 24-Hr ω-hydroxy, ω-
1/ω-2 hydroxy and total vitamin E metabolite excretion in wild-type (solid bar) and L-Cpr-/- 
mice (open bar) were quantified by GC-MS.  Asterisks indicate significant differences from 
wild-type.  B. 24-Hr fecal excretion of unmetabolized TOH in wild-type (solid bar) and L-Cpr
-/-
 
mice (open bar).  C. Concentration of TOHs in plasma and tissues of wild-type (solid bar) and 
L-Cpr
-/-
 mice (open bar) fed the supplemented diet for 4 weeks.  Asterisks indicate significant 
differences from L-Cpr-null mice (p<0.05).   
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Tissue TOH status of L-Cpr
+/+
 and L-Cpr
-/-
 supplemented with γ- and δ-TOHs – α-
TOH concentrations in L-Cpr-null mice were 50% those of wild-type mice in every tissue 
analyzed (Fig. 2.2C).  δ-TOH concentrations in the lung, heart, and fat of L-Cpr-null mice were, 
on average, 43% those of wild-type mice.  No other significant differences in tissue TOH status 
between genotypes were observed. 
Intestinal musoca microsomal vitamin E-ω-hydroxylase activity in L-Cpr-/- mice – 
Microsomes prepared from small intestinal musoca of L-Cpr
+/+ 
and L-Cpr
-/-
 mice displayed 
intestinal vitamin E-ω-hydroxylase activity toward δ-, γ- and α-TOHs.  The 13'-OH oxidation 
products were identified on the basis of retention times, expected molecular ions (562.6, 576.6, 
and 590.6, respectively), expected fragment ions (209.0, 223.0, 237.0, respectively) and their 
ratios (Fig. 2.3).   
TOH-ω-hydroxylase activity in human intestine microsomes and human liver 
microsomes – HLM and HIM displayed ω-hydroxylase activity toward δ-, γ-, or α-TOH (Fig. 
2.4).  The rank order of activity by substrate for HLM is γ>δ>>α and that for HIM was γ=δ>>α.  
HIM displayed ω-hydroxylase activity that was 20-30% that of HLM for the three substrates.   
TOH metabolites in human fecal material – Fecal material from an individual 
supplemented with 400 mg/kg/day γ-TOH contained all six γ-carboxychromanol metabolites as 
well as the 13'-OH, 12'-OH and 11'-OH metabolites.  The sum of ω-hydroxy metabolites 
comprised 80% of total metabolites with the remaining 20% was the 12'-OH and 11-OH 
metabolites.  Fecal material from an individual supplemented with 400 mg/kg/day α-TOH 
contained the 3', 7', and 11'-α-carboxychromanols and the 13'-OH, 12'-OH and 11'-OH 
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Figure 2.3. Evidence of TOH-ω-hydroxylase activity in microsomes prepared from mouse liver (A, B, C) and small intestinal 
musoca (D, E, F).  GC-MS chromatograms from incubations of liver microsomes with (A) 250 µM α-TOH, (B) 80 µM γ-TOH, and 
(C) 80µM δ-TOH, illustrating formation of the corresponding 13'-OH metabolites.  Microsomes from mouse small intestinal mucosa 
were incubated with (D) 250 µM α-TOH, (E) 80 µM γ-TOH, and (F) 80µM δ-TOH, illustrating formation of the corresponding 13'-
OH metabolites, demonstrating vitamin E-ω-hydroxylase activity in mouse intestine.  Retention times and the ratio of the molecular 
ion to the fragment ion of intestinal samples were consistent with that of the liver. 
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Figure 2.4. TOH-ω-hydroxylase activity in pooled human liver microsomes (A, B, C) and pooled human intestinal microsomes 
(D, E, F).  GC-MS chromatograms from incubations of human liver microsomes with (A) 250 µM α-TOH, (B) 80 µM γ-TOH, and 
(C) 80µM δ-TOH, illustrating formation of the corresponding 13'-OH metabolites.  Human intestinal mucosal microsomes were 
incubated with (D) 250 µM α-TOH, (E) 80 µM γ-TOH, and (F) 80µM δ-TOH, illustrating the formation of the corresponding 13'-OH 
metabolites, demonstrating vitamin-E-ω-hydorxylase activity in human intestine.  Retention times and the ratio of the molecular ion to 
the fragment ion of intestinal samples were consistent with that of the liver. 
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metabolites.  ω-hydroxy metabolites represented 30% of total metabolites while the 12'-OH and 
11'-OH metabolites comprised the remaining 70%. 
Discussion 
We previously reported that CYP4F14 is the major vitamin E-ω-hydroxylase in the 
mouse and that its disruption in mice fed a soybean oil diet containing modest amounts of γ-TOH 
resulted in elevated tissue levels of γ-TOH relative to wild-type mice (39).  The accumulation of 
γ-TOH occurred despite two counterbalancing mechanisms, namely 1) higher excretion of 
unmetabolized γ-TOH and 2) elevated excretion of novel ω-1 and ω-2 metabolites of γ-TOH.  
The previous studies also revealed the presence in mice of ω-hydroxylase activity not mediated 
by CYP4F14. The current work aimed to further characterize the role of vitamin E-ω-
hydroxylase in limiting tissue accumulation of TOHs.  Specifically, we investigated whether 
dietary supplementation with high levels of γ- and δ-TOHs would overcome the 
counterbalancing effects and result in tissue enrichment above that seen with the previous 
soybean oil diet.  Two experimental models were employed: mice with global disruption of 
Cyp4f14 and mice with liver-specific disruption of Cpr both supplemented with high levels of γ- 
and δ-TOH.  
Supplementation with γ- and δ-TOHs resulted in substantial increases in tissue levels of 
these forms in both wild-type and knockout mice relative to mice previously fed a soybean oil 
diet.  The increases in tissue levels (7 to 25-fold) were similar or greater than the increase in 
dietary levels (5-10 fold).  While the fold-difference in tissue γ- and δ-TOHs between knockout 
and wild-type mice was similar to that previously observed in unsupplemented mice, the absolute 
difference in tissue levels was substantially greater.  For example, the effect of Cyp4f14 
50 
 
disruption resulted in an increase of 14 nmol/g γ-TOH in the liver of unsupplemented mice, but 
an increase of 100 nmol/g in liver of supplemented mice, despite being a 2-fold difference 
between genotypes in both cases.  The combination of supplementation and Cyp4f14 disruption 
resulted in a 14-fold increase (186 nmol/g) in liver γ-TOH, illustrating the potential of this model 
to study the biological consequences of tissue enrichment with specific forms of vitamin E.  
 Interestingly, female mice accumulated significantly more vitamin E in many tissues 
compared to their male counterparts, irrespective of genotype.    Due to the small sample size, 
statistical analysis of metabolic cage data was not possible, although it does not appear that 
females metabolize vitamin E to a different extent than males.  The reason for this gender effect 
and its consequences are unknown but warrants further investigation.  The dramatic elevation in 
tissue γ- and δ-TOH occurred in the absence of any overt detrimental effects.  
Unlike any other tissue in Cyp4f14
-/-
 and wild-type mice, adipose tissue displayed higher 
levels of δ-TOH compared to γ-TOH, despite similar levels of these forms in the diet.  One 
possible explanation for this finding is that adipose tissue may have vitamin E metabolizing 
capability such that γ-TOH is being metabolized to a greater extent than δ-TOH.  The 
concentration of δ-TOH was not affected by the disruption of Cyp4f14, indicating any vitamin E 
metabolizing capability in the adipose tissue is through a CYP4F14-independent mechanism.  
We observed higher levels of unmetabolized fecal γ-TOH than δ-TOH in both Cyp4f14-/- and 
wild-type mice, which could also be contributing to higher δ-TOH levels in adipose tissue.   
Cyp4f14 disruption in supplemented mice resulted in substantial loss of whole-body 
vitamin E-ω-hydroxylase activity (80%), the magnitude of which was similar to that observed 
unsupplemented mice.  While not statistically significant, the higher level of 11'- and 12'-OH 
metabolites excreted in Cyp4f14
-/-
 supplemented mice resulted in attenuation of the overall 
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metabolic deficit (40%).  The counterbalancing effect of these alternative pathways was still an 
important mechanism in limiting tissue TOH accumulation in the context of supplementation.   
Supplemented mice of both gentotypes excreted substantial quantities of unmetabolized 
TOHs which constituted a significant mechanism of resistant to tissue TOH accumulation.  
Whether this resulted from decreased intestinal absorption or increased biliary secretion of 
tocopherols is unknown. In contrast to what is seen in the unsupplemented state, the excretion of 
unmetabolized TOHs did not constitute a counterbalancing effect in the Cyp4f14
-/-
 mice.  In the 
supplemented mice, fecal TOH elimination was a more important means of disposal of dietary 
TOHs than was metabolic elimination.  In wild-type mice fecal TOH elimination was 5 times 
that of whole-body metabolic disposal, whereas in knockout mice fecal TOH disposal was 10-
fold that of metabolic disposal.  In this respect, fecal elimination of unmetabolized TOHs served 
as a high capacity mechanism of resisting tissue accumulation of dietary TOHs under conditions 
of supplementation.  These findings suggest that supplementation was not able to completely 
overcome the mechanisms of resistance of tissue accumulation constituted by vitamin E 
metabolism and fecal TOH excretion. 
Mice exhibit multiple hepatic TOH-hydroxylase activities in the absence of CYP4F14 
that influence diet induced tissue levels of TOHs.  Therefore, we utilized L-Cpr
-/-
 mice, in which 
all hepatic CYP activity was absent.    If vitamin E metabolizing capacity was restricted to the 
liver, then these mice should completely lack the ability to metabolize vitamin E.  However, in 
L-Cpr
-/-
 mice supplemented with γ- and δ-TOH, whole body metabolic capacity was only 
reduced by 70%, clearly demonstrating the presence of extra-hepatic ω, ω-1, and ω-2 
hydroxylation activities.   
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Despite significant reductions in vitamin E metabolism in L-Cpr
-/-
 mice supplemented 
with γ- and δ-TOHs, tissue levels of all three TOHs were similar to or actually lower than those 
of wild-type mice.  This finding may have resulted from a reduced efficiency of TOH absorption 
secondary to the inability to synthesize bile acids.  Liver-specific disruption of Cpr has been 
shown to cause 90% reduced bile acid production due to the disruption of CYP7A1 in the liver, 
the rate-limiting step of neutral bile acid biosynthetic pathway (41).  This feature additionally 
complicates the interpretation of the 70% reduction in whole-body in vivo metabolic capacity, 
and could underestimate the magnitude of extra-hepatic metabolic activity. 
We sought to determine potential sites of the vitamin E hydroxylase activities present in 
L-Cpr
-/-
 mice.  Since many P450s are expressed in the small intestine, we evaluated that tissue 
and found ω-hydroxylase activity several forms of vitamin E, although at levels less than that of 
liver.  The contribution of the intestine to whole-body vitamin E metabolic activity is at present 
unknown but can be investigated using intestine-specific Cpr knockout mice.  We additionally 
confirmed the presence of vitamin E hydroxylase activity in human small intestinal mucosa 
microsomes, validating the mouse as a model to investigate the role of the intestine in first pass 
vitamin E metabolism. 
The ω-1 and ω-2 hydroxylations of δ- and γ-TOH represented quantitative important 
mechanisms of vitamin E metabolism, accounting for up to 30 percent of whole-body vitamin E 
metabolites in wild-type mice.   The relevance of this finding to human vitamin E metabolism 
was demonstrated by the identification of all ω-0, ω-1, and ω-2 hydroxy metabolites of γ-TOH in 
human feces.  We additionally identified several fecal ω-hydroxy metabolites and both ω-1 and 
ω-2 metabolites of α-TOH, the most commonly used form of vitamin E supplement.   The 
enzyme(s) responsible for the ω-1 and ω-2 activities in mice and humans are unknown.  The 
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finding of these metabolites in fecal material raised the possibility that may have arisen from the 
action of gut microflora. However, this is unlikely since we observed no difference in their 
concentration in intestinal contents above versus below the cecum (data not shown).  
Additionally, ceacal samples, with or without a heat treatment sufficient to kill bacteria, were 
incubated for 24 hrs at 37˚C followed by treatment with deconjugation enzymes.  The 
concentration of ω-1 and ω-2 metabolites was not affected by heat treatment, further supporting 
the lack of a role of intestinal microflora in the production of these novel metabolites.  The 
presence of these metabolites in the bile of mice indicates that these are likely of hepatic origin.   
In summary, supplementation with high levels of γ- and δ-TOH results in tissue 
enrichment with these forms of vitamin E, and this enrichment is enhanced by the disruption of 
CYP4F14, the major murine TOH-ω-hydroxylase.  However, at these high dietary levels of 
TOHs, other mechanisms which serve to limit tissue enrichment become more important than the 
role of the ω-hydroxlyase pathway.  These mechanisms consist of the ω-1 and ω-2 hydroxylase 
pathways and fecal elimination of unmetabolized TOHs, the latter predominating under 
conditions of supplementation.  The use of L-Cpr
-/-
 mice, which completely lack all hepatic 
vitamin E hydroxylase activity, revealed the presence of extra-hepatic vitamin E metabolism in 
vivo.  TOH-ω-hydroxylase activity was observed in the musoca of the small intestine, the first 
report that a tissue other than the liver is capable of metabolizing vitamin E.  These findings were 
extended to humans with the observations of vitamin E-ω-hydroxylase activity in human 
intestinal mucosa and fecal excretion of ω-1 and ω-2 metabolites.  These findings shed new light 
on the role of TOH-ω-hydroxlyase activity and other mechanisms in preventing diet induced 
accumulation of vitamin E in mice and further characterizes vitamin E metabolism in mice and 
humans.   
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CHAPTER 3 
COMMON VARIANTS OF CYTOCHROME P450 4F2 EXHIBIT ALTERED VITAMIN E-
OMEGA HYDROXYLASE SPECIFIC ACTIVITY 
Introduction 
Cytochrome P450 4F2 (CYP4F2) is an ω-hydroxylase that catalyzes the first step in the 
only known pathway of vitamin E metabolism, the tocopherol-ω-oxidation (TOH-ω-oxidation) 
pathway (14, 18).  CYP4F2 was initially characterized as catalyzing the ω-hydroxylation of 
leukotriene B4 (LTB4) as well as arachidonic acid (AA) (42, 43).  The ω-hydroxylation of the 
terminal methyl group of the phytyl side chain of vitamin E to form the 13 -OH product is 
followed by the truncation of the molecule into short chain, more water soluble 
carboxychromanol metabolites that are excreted in urine (19-21).  Like all CYP enzymes, 
CYP4F2 is part of an endoplasmic reticulum membrane-bound complex that requires the CYP 
enzyme itself and reducing equivalents from NADPH via the electron donor cytochrome P450 
reductase.  While CYP4F2 shares its activity towards AA and LTB4 with several other P450 
enzymes, there is no known redundancy in TOH-ω-hydroxylase activity.   
Vitamin E is the generic term for several chemical structures including α-,γ-, and δ-
tocopherol (TOH) containing a saturated phytyl side chain and having three, two and one methyl 
group on the chromanol ring, respectively.  The corresponding α-,γ-, and δ-tocotrienols (T3) 
have three double bonds in the phytyl side chain.  CYP4F2 exhibits profound substrate 
preference for non-α-TOH forms of vitamin E (15).  In addition, the hepatic α-TOH transfer 
protein (α-TTP) preferentially promotes the secretion of α-TOH from the liver into the 
bloodstream for transport to tissues (16).  Together, these two proteins comprise an effective 
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mechanism that results in the selective accumulation of α-TOH in tissues, and the elimination of 
other forms of vitamin E, regardless of the relative proportions of each form in the diet (15).   
Plasma α-TOH concentrations and responses to supplementation in clinical trials vary 
widely within a healthy population but are consistent within individuals, lending support to the 
idea that α-TOH status is a genetically determined trait (44).  Due to the apparent importance of 
the TOH-ω-oxidation pathway in vitamin E status, it has been suggested that individual single 
nucleotide polymorphisms (SNP) in the CYP4F2 gene may contribute to variation in vitamin E 
status in humans (45).  Recently, two non-synonymous SNP in the CYP4F2 gene have been 
identified: a T to G nucleotide change at mRNA position 84 leading to a tryptophan to glycine 
substitution at amino acid position 12 (rs3093105; W12G) and a G to A nucleotide change at 
mRNA position 1347 leading to a valine to methionine substitution at amino acid position 433 
(rs2108622; V433M).  The W12G variant has a minor allele frequency of 11% and 21% in the 
European-American and African-American populations examined, respectively, while the 
V433M variant has a minor allele frequency of 17% and 9%, respectively (46).  Using a 
combined Asian sampling panel (Chinese and Japanese HapMap dataset) the minor allele 
frequency for the W12G variant and the V433M variant are 6% and 26%, respectively (46).  The 
existence of the double mutant in humans has yet to be reported.  Recently, the V433M 
polymorphism has been associated with altered warfarin dose requirements in humans (47) as 
well as hypertension (48) and ischemic stroke in several populations (48-50).  Speculative 
mechanisms behind these associations relate to the role of CYP4F2 in 20-HETE production and 
the putative role of CYP4F2 as a vitamin K1 oxidase (51). 
A previous study demonstrated that the V433M substitution in CYP4F2 results in 
decreased ω-hydroxylation of AA (46).  The purpose of this study was to determine if the amino 
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acid substitutions resulting from these two non-synonymous SNP in CYP4F2 cause altered 
vitamin E-ω-hydroxylase specific activity, using several major dietary forms of vitamin E as 
substrates. 
 
Materials and Methods 
Chemicals and materials.  Tocopherols were obtained from Matreya, LLC (Pleasant 
Gap, PA).  The tocotrienols were a gift from Volker Berl (BASF, Ludvigshafen, Germany).  Sf9 
insect cells were provided by W. Lee Kraus (Cornell University).  Insect cell media was 
purchased from BD Biosciences (San Diego, CA).  Insect cell certified fetal bovine serum (BSA) 
was purchased from Atlanta Biologicals (Lawrenceville, GA) and antibiotic-antimycotic solution 
was purchased from Mediatech, Inc. (Hemdon, VA).  ß-NADPH, hemin chloride, 5-
aminolevulinic acid, ferric citrate, and fraction V bovine serum albumin were purchased from 
Sigma Chemical Co. (St. Louis, MO).  The internal standard d9-α-TOH was custom-synthesized 
by J. Swanson (Cornell University).  Pyridine and N,O-bis-[trimethylsilyl]trifluoracetamide 
containing 1% trimethylchlorosilane were purchased from Pierce Chemical Co. (Rockford, IL).  
Insect cell microsomes (BD Supersomes) containing human CYP4F2, cytochrome P450 
reductase and cytochrome b5 were purchased from Gentest (Woburn, MA).  PVDF membranes, 
Odyssey blocking buffer, and IRDye 680 conjugated goat (polyclonal) anti-rabbit IgG were 
purchased from Li-Cor Biosciences (Lincoln, NE).  Rabbit anti-human 4F2 polyclonal antibody 
was obtained from Fitzerald Industries (Concord, MA).  Arachidonic acid and 20-
hydroxyeicosatetraenoic acid (20-HETE) were purchased from Cayman Chemical (Ann Arbor, 
MI).    
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Generation of baculovirus. Recombinant baculovirus preparations containing four 
human CYP4F2 enzyme isoforms (wild-type W12/V433, position 12 variant G12/V433, position 
433 variant W12/M433, and the double variant G12/M433) were generated by Stec et al as 
previously described (46).  The vector contained two promoters that independently drive the 
expression of CYP4F2 and of the required co-enzyme cytochrome P450 reductase. 
  Preparation of microsomes containing CYP4F2 variants. Sf9 cells were infected with 
recombinant baculovirus at multiplicity of infection of 5-10.  Sf9 cells were grown in insect cell 
media with 10% fetal bovine serum and antibiotic-antimycotic solution.  At the time of infection, 
the media was supplemented with hemin (conjugated to bovine serum albumin; 4 µmol/L), 5-
aminolevulinic acid (0.5 mmol/L) , and ferric citrate (100 μmol/L).  The cells were incubated at 
27°C for 3 days following infection.  After this time, cells were collected, washed with 
phosphate buffered saline, resuspended in homogenization buffer (0.1 mol/L sodium phosphate 
buffer containing 10% glycerol, 1 mmol/L EDTA, 0.1 mmol/L DTT, 1 mmol/L PMSF, pH 7.5) 
and frozen at -80°C.  The cells were then thawed, homogenized using a dounce homogenizer and 
centrifuged at 10,000 x g for 20 min at 4°C.  The supernatant was then subjected to high speed 
centrifugation at 100,000 x g for 1 h at 4°C.  The microsomal pellet was resuspended in 0.1 
mol/L sodium phosphate containing 20% glycerol, 1 mmol/L EDTA, 0.1 mmol/L DTT and 0.2 
mmol/L PMSF and stored at -80°C.  Total microsomal protein concentration was measured using 
a Bradford-based Bio-Rad assay with BSA as the standard.  In addition, negative control Sf9 
cells that did not receive virus were prepared in triplicate as described above. 
Measurement of CYP4F2 protein. Western blots to quantify recombinant CYP4F2 
protein were performed on the microsomes prepared from Sf9 cells.  A standard curve of human 
CYP4F2 (4F2 Supersomes) was run on each gel.  The amount of microsomal protein 
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concentration that was loaded in each lane varied between samples in order to ensure each 
sample was within the standard curve that was run on each blot.  Between 47 and 100 μg of 
microsomal protein were heated to 95°C for 5 minutes, electrophoresed on 12% SDS-
polyacrylamide gels, and blotted onto PVDF membrane.  Membranes were blocked with 
Odyssey blocking buffer for 2 h at room temperature and then incubated with rabbit anti-human 
4F2 polyclonal antibody (1:300).  The membranes were then incubated with IRDye 680 
conjugated goat (polyclonal) anti-rabbit IgG for 1 h at room temperature.  The membranes were 
visualized using an Odyssey infared imager (Li-Cor, Lincoln, NE) with densiometric analysis 
performed using Odyssey software.   The concentration of CYP4F2 protein in the microsomal 
preparations prepared from each human CYP4F2 variant was derived from the standard curve on 
each individual blot. 
Measurement of vitamin E-ω-hydroxylase activity. A comparison of CYP4F2-dependent 
vitamin E-ω-hydroxylase activity among the four enzyme isoforms using Sf9 microsomes 
obtained from three independent transfection batches was first determined using δ-TOH as 
substrate.  The reaction system (0.5 mL) consisted of sodium phosphate (NaP) buffer (0.1 mol/L, 
with 0.1 mmol/L EDTA, pH=7.4), 60 μmol/L δ-TOH added as a complex with 1% (w/v) fraction 
V BSA prepared as previously described (15), and the volume of each of the four microsomal 
preparations sufficient to achieve equivalent total microsomal protein concentration.  
Microsomes were preincubated with the substrate-BSA complex at 37°C for 5 min after which 
point NADPH was added to a final concentration of 2 mmol/L and the system incubated for 35 
min at 37°C.  The reaction was terminated and δ-13’-OH-TOH product extracted and derivitized 
as previously described (15). d9-α-TOH was used as internal standard. 
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An investigation of the impact of the single and double mutations using several 
tocopherols (α-, γ-TOH) and tocotrienols (α-, γ-, δ-T3) as substrate was then performed using 
microsomes from the same transfection batch.  Conditions for evaluation of ω-hydroxylation of 
γ-TOH were similar to that of δ-TOH described above.  Those used for assay of metabolism of 
α-TOH and tocotrienols were similar except for substrate concentrations (α-TOH, 350 μmol/L; 
tocotrienols, 10 μmol/L) to account for differences in membrane uptake as characterized 
previously (15).  In addition, several of these substrates were assayed at a lower concentration (γ-
, δ-TOH: 30 μmol/L; α-T3: 4 μmol/L).  The analogous 13'-ω-hydroxylated reaction products 
were extracted and derivatized as described above. 
Measurement of arachidonic acid ω-hydroxylation. Assays to determine the AA-ω-
hydroxylase specific activity were performed in NaP buffer with 42 μmol/L AA without BSA, 
and an equal amount of microsomal protein from each of the four microsomal preparations from 
one transfection batch in 0.5 mL reaction volume.  Reaction mixtures were preincubated for 5 
min at 37°C after which time NADPH (2 mmol/L) was added and incubations continued for 35 
min at 37°C.    20-HETE was extracted and derivatized after acidification as described above, 
using d9-α-TOH as internal standard. 
GC-MS. A Hewlett-Packard 6890 gas chromatograph, coupled to a Hewlett-Packard 
5872 mass selective detector operated in selected ion mode, was used for quantification of 
vitamin E and AA reaction products.  The gas chromatograph was fitted with a Hewlett-Packard 
HP-1 methylsiloxane capillary column (30 m X 0.25 mm) and operated in split injection mode 
using helium as the carrier gas.  Long-chain TOH and T3 metabolites were resolved isothermally 
at 280°C for 20 minutes.  20-HETE was resolved using a temperature program starting at 180°C, 
ramping to 250°C at a rate of 6°/min, then to 280°C at a rate of 25°/min, holding at 280°C for 13 
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min.  Metabolite product was quantified using the d9-α-TOH internal standard.  20-HETE values 
were corrected using a relative detector response factor of 50. 
Calculation of enzyme specific activity. Enzyme activity data (pmol product/min) were 
normalized to the microsomal CYP4F2 protein content as determined by quantitative Western 
blotting to yield specific activity (pmol 
• 
min
-1 • 
pmol 4F2
-1
).  Data are presented as specific 
activity or as percentage of wild-type specific activity. 
Statistical analysis. Three independent transfection batches of the four microsomal 
enzyme isoform preparations were each assayed in triplicate for the initial comparison of specific 
activities using δ-TOH as substrate.  Each of the three batches was analyzed independently using 
one-way ANOVA.  When significant main effects of enzyme isoform were detected, post hoc 
multiple comparisons were performed using a Tukey correction.  The comparison of specific 
activities of the four enzyme isoforms using various tocopherol and tocotrienol substrates was 
performed in triplicate using the same transfection batch.  In order to assess the effect of enzyme 
isoform on CYP4F2 specific activity, Student’s t-test was used to compare the specific activity 
of each variant enzyme to that of the wild-type enzyme for each substrate individually.  In 
addition, for each of the three variants, the mean percent of wild-type value for each tocopherol 
substrate was compared to the mean percent of wild-type value of the other two tocopherol 
substrates using one-way ANOVA followed by multiple comparisons with a Tukey correction.  
Similarly, for each of the three variants, the mean percent of wild-type value for each tocotrienol 
substrate was compared to the mean percent of wild-type value for the other two tocotrienol 
substrates using one-way ANOVA followed by multiple comparisons with a Tukey’s correction.  
Differences in arachidonic acid-ω-hydroxylase specific activity between the four enzyme 
isoforms were determined using one-way ANOVA followed by multiple comparisons with a 
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Tukey’s correction.  Values in the text are means ± SD.  All statistical analyses were performed 
using JMP version 8 (SAS Institute Inc.).  If needed, responses were log-transformed to meet the 
assumptions of the statistical tests.  All tests were 2-sided, and P < 0.05 was considered to 
constitute statistical significance. 
 
Results  
Expression of CYP4F2 variants in Sf9 microsomes. A 53-kDA protein that co-migrated 
with human CYP4F2 standard was observed in each of the four CYP4F2 microsomal 
preparations (W12/V433 [WT], G12/V433, W12/M433, G12/M433).  A representative blot from 
one of the transfection batch is shown in Figure 3.1.  Negative control microsomal preparations 
did not show a band at 53-kDA (Figure 3.1B). 
 
 
 
Figure 3.1. CYP4F2 expression of four enzyme isoforms in Sf9 microsomal 
preparations.  Lanes 1-4: CYP4F2 standard of 0.05, 0.10, 0.15 and 0.20 pmoles, 
respectively.  Lanes 5-8, CYP4F2 isoforms: WT, W12G, V433M, W12G/V433M, 
respectively, (A). Lanes 9 and 10 (from a separate blot): CYP4F2 standard of 0.15 
pmoles and negative control microsomes, respectively, (B). Western blotting 
using antibodies against CYP4F2 detected a 53-kDa protein that co-migrated with 
CYP4F2 standard.  Blots are representative of three independent transfection 
batches.   
 
δ-TOH ω-hydroxylase specific activity of wild-type and variants of CYP4F2.  All 
assayed microsomal preparations except the negative controls showed production of δ-13’-OH-
TOH as determined by electron impact mass spectroscopy.  Analysis of log-transformed data 
from one transfection batch indicated the mean δ-13’-OH-TOH production of wild-type enzyme 
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was significantly different from the three variants after normalization to microsomal CYP4F2 
protein content (Figure 3.2).  The W12G substitution resulted in significantly higher δ-13’-OH-
TOH production (275% of wild-type enzyme, P < 0.0001) compared to wild-type.  In contrast, 
the amino acid substitution at position 433 resulted in decreased δ-13’-OH-TOH production 
(66% of wild-type enzyme, P < 0.02).  The effect of the double mutation was the same as the 
single mutation at position 433, exhibiting diminished specific activity (60% of wild-type 
enzyme, P < 0.007).  Microsomal preparations from all three transfection batches showed similar 
differences in specific activity due to the mutations, except that in one batch the activity of the 
double mutant was not statistically different from that of wild-type (data not shown).  The 
relative enzyme specific activities using 30 μM δ-TOH were consistent with the results observed 
using 60 μM δ-TOH.  The W12G variant exhibited 145% of wild-type enzyme specific activity, 
while the V433M variant and the double variant exhibited 37% and 66% of wild-type specific 
activity, respectively, at the lower concentration. 
 
 
 
 
 
 
 
 
Figure 3.2. δ-TOH-ω-hydroxylase specific activity of CYP4F2 isoforms. δ-13 -
OH-TOH formation was determined in microsomal incubations containing 60 
μmol/L δ-TOH-BSA complex.  Data are means ± SD, n=3. Means without a 
common letter differ, P < 0.05. 
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Comparative metabolism of various tocopherols and tocotrienols by CYP4F2 variants.  
The W12G enzyme variant exhibited significantly greater specific activity toward all three 
tocopherols tested (255 ± 22 percent of wild-type, P < 0.0001, Figure 3.3A).  In sharp contrast, 
the V433M enzyme variant exhibited significantly decreased ω-hydroxylase activity toward all 
three tocopherols (57 ± 14 percent of wild-type, P < 0.03, Figure 3.3B).  Among the tocopherol 
substrates, α-TOH was the most negatively impacted by the V433M substitution, but was the 
least impacted by the gain-of-function effect of the W12G substitution.  The W12G/V433M 
double mutant exhibited reduced specific activity toward all three tocopherols, similar to what 
was observed for the V433M variant (48 ± 14 percent of wild-type, P < 0.002, Figure 3.3C).  
The relative specific activities of the enzyme isoforms obtained using 30 μM γ-TOH were 
consistent with those observed using 60 μM γ -TOH, with the W12G variant resulting in 162% 
of wild-type specific activity, while the V433M variant and the double variant exhibited 47% 
and 68% of wild-type specific activity, respectively, at the lower concentration. 
As was the case with tocopherol substrates, the W12G variant exhibited much higher 
specific activities toward all three tocotrienol substrates (353 ± 2 percent of wild-type, P < 0.003, 
Figure 3.4A).  In contrast, the V433M substitution had little or no effect on specific activity 
toward the tocotrienols, with a marginally significant difference from wild-type evident with δ-
T3 as substrate (P = 0.046, Figure 3.4B).  Again, results of the double mutant were similar to 
those obtained with the V433M variant (Figure 3.4C).  In contrast to the case with tocopherols, 
none of the three variants exhibited significant differences in specific activity among the three 
tocotrienol substrates.  Additionally, the relative specific activities of the enzyme isoforms 
obtained using 4 μM α-T3 were consistent with those observed using 10 μM α -T3.  The W12G 
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variant exhibited 203% of wild-type specific activity while the V433M variant and the double 
variant exhibited 84% and 106% of wild-type specific activity at the lower concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Alterations in ω-hydroxylation of tocopherols by CYP4F2 
isoforms W12G (A), V433M (B), W12G/V433M (C).  Enzyme specific activity 
(pmol product 
• 
min
-1 • 
pmol CYP4F2
-1
) for each of the three variants is expressed 
as percent of the wild-type activity value.  Dotted line represents 100%, i.e. wild-
type.  Data are means ± SD for each tocopherol evaluated, n=3.  *different from 
wild-type, P < 0.03.  Within each graph, means without a common letter differ, P 
< 0.05. 
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Figure 3.4. Alterations in ω-hydroxylation of tocotrienols by CYP4F2 isoforms 
W12G (A), V433M (B), W12G/V433M (C).  Enzyme specific activity (pmol product 
• 
min
-1 • 
pmol CYP4F2
-1
) for each variant is expressed as percent of the wild-type activity 
value.  Dotted line represents 100%, i.e. wild-type.  Data are means ± SD for each 
tocotrienol evaluated, n=3.  *different from wild-type, P < 0.05.  Within each graph, no 
means were significantly different from each other (P > 0.05). 
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ω-Hydroxylation of arachidonic acid by CYP4F2 variants. In light of the finding of a 
significant gain-of-function effect of the W12G variant on vitamin E metabolism, the four 
enzyme isoforms were re-evaluated with respect to arachidonic acid ω-hydroxylation.  The 
specific activity of the W12G variant was significantly greater than that of wild-type enzyme 
(190% of wild-type enzyme, P < 0.0009, Figure 3.5).  The V433M variant exhibited a severe 
loss-of-function (20% of wild-type enzyme, P < 0.0009), an effect similar to the loss-of-function 
observed with the double mutant (22% of wild-type enzyme, P < 0.0009).  Thus, the effects of 
the three variants on ω-hydroxylation of arachidonic acid mirrored the effect of the ω-
hydroxylation of the three tocopherols. 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Metabolism of arachidonic acid by CYP4F2 isoforms.  20-HETE 
formation was determined in incubations containing 42 μmol/L AA.  Data are 
means ± SD, n=3. Arachidonate ω-hydroxylase specific activity was compared 
between the four enzyme isoforms.  Means without a common letter differ, P < 
0.05.   
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Discussion 
CYP4F2 catalyzes the initial step in the only known enzyme-mediated pathway of 
vitamin E metabolism, the vitamin E-ω-oxidation pathway (14).  The product of the reaction, the 
hydroxyl derivative of one of the two terminal methyl groups of the hydrophobic side chain, then 
undergoes further metabolism to polar carboxychromanols that are excreted in the urine.  No 
other major human liver CYP enzymes exhibit this enzyme activity (18) and thus unlike many 
other CYP-catalyzed reactions, redundancy of function appears lacking.  CYP4F2 exhibits 
pronounced substrate specificity among the various naturally occurring forms of vitamin E, such 
that those forms with incomplete methylation of the phenol ring or with unsaturated side chains 
are metabolized more rapidly (15).  Consequently CYP4F2 appears to play a unique role in the 
post-absorptive catabolism of vitamin E that contributes, along with the hepatic α-TTP, to the 
widely-expressed phenotype of selective tissue deposition of α-tocopherol over other forms of 
vitamin E.  Here we tested the hypothesis that two common mutations in the human CYP4F2 
gene would alter the activity of the enzyme toward vitamin E substrates.  Consistent with this 
hypothesis, the W12G variant exhibited significantly greater ω-hydroxylase specific activity 
toward the three tocopherols tested and all the three tocotrienols tested.  In sharp contrast, the 
V433M variant exhibited significantly lower specific activity toward the tocopherols, but was 
without significant effect with the tocotrienol substrates.  Two tocopherols and one tocotrienol 
were also tested at lower concentrations, and the relative specific activities of the four enzyme 
isoforms were consistent across both substrate concentrations.  All concentrations tested were 
either near or substantially below the apparent Km for tocopherol-ω-hydroxylase activity in 
human liver microsomes (15). 
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Our previous characterization of wild-type CYP4F2 activity toward a wide variety of 
naturally occurring and synthetic vitamin E substrates indicated that the tocotrienols were in 
general metabolized more readily than the tocopherols (15).  The directionality of the effects of 
the two common SNP investigated here, in comparison to the wild-type enzyme, indicates that 
the tocotrienol-over-tocopherol substrate preference is retained, if not accentuated, in those 
variants.  The biological rationale for the observed differences in catabolism of the different 
forms of vitamin E, even amongst the polymorphic forms of CYP4F2, remains an enigma.  
Accumulation of tocotrienols or tocopherols that are subject to higher rates of catabolism have 
been reported to result in beneficial effects in animal models (32, 52, 53) and cytotoxic effects in 
cell culture models (54, 55). 
In the first reported investigation of the functional effects of the W12G and V433M 
variants of CYP4F2, Stec et al (46) reported a loss of arachidonic acid ω-hydroxylase activity by 
the V433M variant and a trend towards higher specific activity accompanying the W12G 
substitution.  Both as a positive control for our findings with vitamin E and to re-evaluate the 
W12G variant in light of the substantial gain-of-function with both tocopherols and tocotrienols, 
we compared arachidonic acid ω-hydroxylase specific activity among the four enzyme isoforms.  
Under our experimental conditions, findings with the V433M variant and double mutant 
mirrored those reported previously, while the W12G variant exhibited a significant 2-fold 
enhancement of specific activity, similar to what was observed with the vitamin E substrates.  
The physiological significance of the latter finding is difficult to evaluate due to the redundancy 
in arachidonate 20-hydroxylase activity among multiple CYP450 enzymes, and the potential for 
compensatory degradation of 20-HETE. 
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The means by which these two amino acid substitutions act to affect enzyme function is 
unclear.  The three dimensional structure of CYP4F2 has not been determined or modeled, thus 
the amino acid residues that participate in substrate binding, channeling and catalysis have not 
been identified.  Sequence heterogeneity in the amino acid 67-114 region of CYP4F3A and 
CYP4F3B correlates with the differences in substrate specificity of these two 4F isoforms, 
suggesting this region may play a critical role in determining substrate specificity of other 
CYP4F enzymes (24), but neither of the current substitutions lie within this putative substrate 
recognition domain.  Other possibilities include alterations in protein structure that affect how 
the enzyme orients in the membrane, which may in turn influence the access by membrane-
bound substrates like vitamin E.  Different forms of vitamin E may reside at different depths in 
biological membranes (56). 
The impact of these two variations in CYP4F2 structure on vitamin E status in humans is 
at present unknown.  Both of the naturally-occurring variants are relatively common in 
European-American and African-American derived sampling panels, as well as in the Chinese 
and Japanese HapMap dataset (46).  In vivo investigations indicate that decreased CYP4F2 
activity results in altered vitamin E status.  Yamashita et al (57) reported that dietary sesamin, a 
sesame seed lignan later found to be an inhibitor of CYP4F2 (35), resulted in elevated 
concentrations of α- and γ-tocopherols in rat serum.  Additionally, short-term administration of 
moderate amounts of sesame seeds to humans resulted in elevations in serum γ-tocopherol levels 
(36).  These findings raise the distinct possibility that the CYP4F2 variants investigated here may 
contribute to variation in vitamin E status.   Plasma α-tocopherol levels and responses to vitamin 
E supplementation are consistent over time within individuals, yet  highly variable between 
individuals, leading to the suggestion that α-tocopherol status is influenced by genetic factors 
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(44).  Individuals carrying one or two of the V433M variant alleles may exhibit increased plasma 
and tissue levels of tocopherols, and display a more pronounced response to tocopherol 
supplementation than individuals carrying wild-type alleles.  In contrast, individuals carrying the 
W12G allele may display lower plasma and tissue levels of tocopherols, and little or no change 
in response to tocopherol or tocotrienol supplementation.  Underlying genetic variability in 
vitamin E status and response to supplementation may contribute to inconsistent and null 
findings in both epidemiological and randomized controlled trials regarding vitamin E status and 
its relationship to disease risk.  These possibilities are currently under investigation. 
In conclusion, two common non-synonymous SNP in the CYP4F2 gene cause significant 
alterations in vitamin E-ω-hydroxylase specific activity in a variant-dependent manner.  The 
W12G variant exhibited increased enzyme activity toward both tocopherols and tocotrienols, 
while the V433M variant exhibited reduced enzyme activity towards tocopherols but not 
tocotrienols.  The effect of these SNP on vitamin E status and response to vitamin E 
supplementation in humans has significant clinical implications and should be investigated.
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CONCLUSION 
 Vitamin E is considered to be the most important lipid-soluble antioxidant in cell 
membranes and lipid stores.  As such, the essentiality of vitamin E for fertility and central 
nervous system function has been well demonstrated.  Despite the wealth of knowledge 
assembled over the decades, there are still aspects of vitamin E metabolism and function that are 
unknown.  Because of the hepatic α-TTP which preferentially binds to α-TOH (in vitro), and the 
TOH-ω-oxidation pathway, which preferentially metabolizes non-α-TOH forms of vitamin E, 
there has never been a model in which to study the biological effects of non-α-TOH forms in 
vivo.  In addition, the importance of the TOH-ω-oxidation pathway in maintaining the α-TOH 
phenotype has never been established in vivo, and the presence of other pathways of vitamin E 
metabolism have yet to be identified.  Therefore, a mouse model was created, which would 
clarify the importance of the TOH-ω-oxidation pathway in vitamin E metabolism and status.  
This model would additionally allow the manipulation of vitamin E status such that the 
biological effects of forms that do not normally accumulate could be investigated.  
 CYP4F2 is the only known human enzyme shown to display TOH-ω-hydroxylase 
activity (14).  Through this work, the functional murine ortholog of CYP4F2 was identified and 
the consequences of its deletion on vitamin E metabolism and status were determined.  As 
hypothesized, CYP4F14 was the major vitamin E-ω-hydroxylase, responsible for as much as 
90% of the metabolic activity in the mouse.  CYP4F14, however, was not the only enzyme 
capable of this activity as knockout mice were still excreting ω-hydroxy metabolites via both the 
urine and the feces.  The enzyme(s) responsible for this redundant TOH-ω-hydroxylase activity 
are currently unknown.  CYP4F14 was shown to have critical function in regulating body-wide 
vitamin E status, even under generally typical dietary conditions.  Disruption of Cyp4f14 
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expression resulted in hyper-accumulation of γ-TOH in plasma and tissues in mice fed a diet 
similar in tocopherol composition to that consumed by many human populations.   
 Because of the experimental design of this study and the analytical capabilities used, 
several novel and important discoveries were made that were not initially envisioned.  Firstly, the 
fecal route of metabolite excretion was found to be as important, if not more important, than the 
urinary route of vitamin E metabolite excretion.  This work was the first to show not only the 
presence of vitamin E metabolites in feces, but also the quantitative importance of these 
metabolites.  Secondly, two novel vitamin E metabolites were discovered, arising from ω-1 and 
ω-2 hydroxylation events.  These novel pathways make up two of the three currently known 
enzyme-mediated pathways of vitamin E metabolism.  Through metabolic cages studies, a 
substantial amount of unmetabolized TOHs were found in the feces of mice.  Interestingly, both 
the fecal excretion of ω-1 and ω-2 metabolites as well as the fecal excretion of unmetabolized 
TOHs were higher in Cyp4f14
-/-
 mice, somewhat counterbalancing the loss of vitamin E 
metabolic function.  Redundancy in vitamin E-ω-hydroxylase activity and the existence of 
counterbalancing mechanisms implies a fundamental biological advantage of resisting diet-
induced accumulation of non-α-TOH forms and maintenance of the α-TOH phenotype.  As a 
result of this work, a new model of vitamin E metabolism has been established (Fig. C.1) with 
three possible metabolic fates of TOHs: ω-0 (13') hydroxylation, ω-1 (12') hydroxylation, or ω-2 
(11') hydroxylation.  While the 13'-OH metabolite can proceed through the ω-oxidation pathway, 
the 12'-OH metabolite is a terminal product.  Whether the 11'-OH metabolite can be further 
oxidized is not currently known.   
 Cyp4f14
-/-
 mice were physiologically normal despite the deficit in vitamin E metabolism, 
although longer term studies have yet to be conducted.  A major question that still remained was  
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Figure C.1: Enzyme-mediated metabolism of vitamin E.  Three pathways of 
enzyme-mediated catabolism are currently known.  Tocopherols can be ω-
hydroxylated by CYP4F2 (human) and CYP4F14 (mouse) and further oxidized 
through the ω-oxidation pathway.  All intermediates can be excreted in the feces 
while only the two smallest-chain metabolites are found in the urine.  
Additionally, tocopherols can undergo ω-1 and ω-2 hydroxylation, the products of 
which are excreted via the feces. 
 
what would occur if these mice were challenged with very high dietary levels of vitamin E forms 
that are normally cleared via the TOH-ω-oxidation pathway.  To answer this question, Cyp4f14-/- 
mice were supplemented with γ- and δ-TOH in order to determine if a dietary challenge would 
allow for higher accumulation of these forms and to assess the physiolocal effect of this 
accumulation.  Supplementation with γ- and δ-TOHs resulted in substantial increases in tissue 
levels of these forms in both wild-type and knockout mice relative to mice previously fed a 
soybean oil diet.  While the fold-difference in tissue γ- and δ-TOHs between knockout and wild-
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type mice was similar to that previously observed in unsupplemented mice, the absolute 
difference in tissue levels was substantially greater, as expected.  Thus, the combination of 
supplementation and Cyp4f14 disruption resulted in substantial tissue enrichment of TOHs, 
illustrating the potential of this model to study the biological consequences of tissue enrichment 
with specific forms of vitamin E.  In supplemented Cyp4f14
-/-
 mice, greater amounts of ω-1 and 
ω-2 metabolites were being excreted, indicating that the counterbalancing effect of these 
alternative pathways was still an important mechanism in limiting tissue TOH accumulation in 
the context of supplementation.  In contrast to what is seen in the unsupplemented state, the 
excretion of unmetabolized TOHs did not constitute a counterbalancing effect in the Cyp4f14
-/-
 
mice, as the levels of these TOHs in the feces was not different between genotypes.  However, in 
the supplemented state, fecal TOH elimination was a more important means of disposal of 
dietary TOHs than was metabolic elimination in both genotypes. In this respect, fecal elimination 
of unmetabolized TOHs serves as a high capacity mechanism of resisting tissue accumulation of 
dietary TOHs under conditions of supplementation.  These findings suggest that supplementation 
was not able to completely overcome the mechanisms of resistance of tissue accumulation 
constituted by vitamin E metabolism and fecal TOH excretion 
Presuming that all of the ω-0, ω-1, and ω-2 activities were present predominantly in the 
liver, a mouse model in which there was no CYP activity in the liver due to the liver-specific 
disruption of Cpr was utilized for further study.  These mice were supplemented with δ- and γ-
TOH, in an attempted to disable the mechanisms that were working against accumulation of non-
α-TOHs.  L-Cpr-/- mice fed the supplemented diet displayed substantial reduction in vitamin E 
metabolite excretion compared to wild-type mice.  Unexpectedly, however, vitamin E 
metabolism was still present in these mice, revealing the presence of extra-hepatic vitamin E 
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metabolism, including ω-0, ω-1, and ω-2 activities.  Due to an the major disruption of bile acid 
synthesis and subsequent inability to absorb lipids, L-Cpr-null mice had lower tissue levels of 
vitamin E compared to wild-type mice.  Thus, the effect of complete disruption of hepatic 
vitamin E hydroxylase disruption on tissue TOH status could not be investigated.  This model 
was, however, very useful in studying the site of extra-hepatic vitamin E metabolism.  
Microsomes from mouse small intestine mucosa of L-Cpr
-/-
 mice displayed TOH-ω-hydroxylase 
activity toward α-, δ-, and γ-TOHs. The capability of vitamin E metabolism in these non-hepatic 
tissues is an extremely novel and important finding which deserves future attention.   
 While observations in mice do not always reflect similar processes in humans, many of 
the findings made through the use of these two knockout mouse models were validated in 
humans.  Analysis of pooled human small intestinal mucosa microsomes demonstrated intestinal 
TOH-ω-hydroxylase activity to be present in the human as well as the mouse.  In mice, the fecal 
route of metabolite excretion was found to be a major route of vitamin E metabolite excretion, a 
fact not previously known.  In humans, fecal metabolites of α- and γ-TOH were also observed 
and should be taken into consideration in future studies of vitamin E metabolism.  Novel 
metabolites of α- and γ-TOH from the ω-1 and ω-2 pathways were observed in human fecal 
material, revealing two novel pathways of vitamin E metabolism in humans.  These pathways are 
quantitatively important pathways of vitamin E metabolism and warrant future research to 
elucidate the enzyme(s) responsible and the location of these pathways.  Factors affecting the 
expression or activity of these enzyme(s) should also be studied, as alterations in vitamin E 
metabolism may lead to differences in vitamin E status as well as the effect of vitamin E intake 
on disease risk and prevention. 
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 Through this work, the TOH-ω-oxidation pathway was found to play an important role in 
vitamin E status under typical dietary conditions.  Therefore, two common mutations in the 
human CYP4F2 gene were studied in a cell culture model in which the wild-type and 
polymorphic genes were separately expressed.  The functional impact of these SNPs on TOH-ω-
hydroxylase activity was studied.  The W12G variant exhibited significantly greater ω-
hydroxylase specific activity toward the three tocopherols tested and all the three tocotrienols 
tested.  In sharp contrast, the V433M variant exhibited significantly lower specific activity 
toward the tocopherols, but was without significant effect with the tocotrienol substrates.  These 
findings raise the distinct possibility that the CYP4F2 variants investigated here may contribute 
to variation in vitamin E status.   Individuals carrying one or two of the V433M variant alleles 
may exhibit increased plasma and tissue levels of tocopherols, and display a more pronounced 
response to tocopherol supplementation than individuals carrying wild-type alleles.  In contrast, 
individuals carrying the W12G allele may display lower plasma and tissue levels of tocopherols, 
and little or no change in response to tocopherol or tocotrienol supplementation.  Underlying 
genetic variability in vitamin E status and response to supplementation may contribute to 
inconsistent and null findings in both epidemiological and randomized controlled trials regarding 
vitamin E status and its relationship to disease risk.  In line with these findings, the V433M 
genotype was recently associated with higher circulating α-TOH concentrations (37) as well as 
response to α-TOH supplementation (58), further supporting the importance of CYP4F2 and 
TOH-ω-hydroxylase activity in vitamin E status. 
 This work provides several interesting areas for future study.  The atypical tissue 
accumulation of non-α-TOH forms of vitamin E in tocopherol supplemented Cyp4f14-null mice 
established this model as a useful model for studying the biological actions of these compounds.  
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Long-term studies should be conducted to determine the physiological effects of non-α-TOH 
tissue accumulation over a lifetime, including reproductive potential.  Additionally, 
supplemented Cyp4f14-null mice can be exposed to various stresses and/or disease states to 
further assess the biological actions of vitamin E, beneficial or detrimental.  Supplemental levels 
of tocotrienols should also be fed to Cyp4f14-null mice, and the metabolism and tissue 
accumulation of these forms should be studied in this context.  These forms may be the most 
likely to have detrimental physiological effects, as they do not typically accumulate to any 
significant extent.  Additionally, as CYP4F2 has been reported to have vitamin K metabolic 
activity, Cyp4f14
-/-
 mice should be utilized to further explore the role of CYP4F14 in vitamin K 
metabolism and status.  Other future studies involve the determination of the enzyme(s) 
responsible for the non-CYP4F14 dependent vitamin E-hydroxylase activities, including ω-0, ω-
1, and ω-2 activities.  These enzymes have been shown here to play an important role in vitamin 
E status, and deserve future attention.  A comprehensive evaluation of extra-hepatic tissues for 
vitamin E metabolic activities should be conducted, including the adipose tissue which displays a 
different pattern of tocopherol composition compared to other tissues.  Lastly, mice with 
intestinal-specific Cpr disruption should be utilized to determine the relative importance of 
intestinal vitamin E-hydroxylase activity to whole-body vitamin E metabolism. 
Overall, the current works lends new insights into the TOH-ω-oxidation pathway as well 
as reveals novel pathways of vitamin E metabolism that are present in both mice and humans and 
play an important role in the regulation of vitamin E status. This work advances the field of 
vitamin E metabolism and provides new directions of future study.  
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